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Chapter I 
GENERAL INTRODUCTION 
1. Need for clinical pharmacological studies in the elderly 
Clinical pharmacology is the medical discipline dealing with 
the scientific study in man of drugs with a proven or expected 
therapeutic value. 
After toxicological and animal experiments, most drugs are stu-
died first in young, healthy, predominantly male volunteers, 
in single dose experiments (phase 1). 
Next, selected patients are studied in short-time experiments 
and clinical trials (phase II and III) . Selection is based on 
the disease studied, and patients with concomitant diseases, 
with co-medication or beyond certain age limits are excluded 
from such studies. However, most drugs are used by non-selec-
ted, old, far from healthy, predominantly female patients on 
a long-term basis and in combination with other drugs for con-
comitant diseases. Knowledge about the pharmacokinetics and 
pharmacodynamics of drugs in this much more common situation is 
incomplete . What is more, the people who use drugs chronically 
are actually the more vulnerable part of the population. These 
considerations prompted us to study geriatric patients in par-
ticular: the old patient with sometimes the need for long-term 
treatment for multiple infirmities. 
2. Choice of drug studied, on the basis of consumption figures 
The drugs most often prescribed in general, and to the elderly 
in particular, are cardiovascular drugs, especially diuretics, 
and psychotropic drugs, including hypnotics; laxatives and 
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analgesics are most often self-prescribed . In The Netherlands, 
the five most prescribed drugs to people over 6 5 are: furo-
semide, nitrazepam, a-methyldopa, chlorthalidone, and the com-
bination of hydrochlorothiazide with amiloride. As many as one 
in four medical in-patients receives a diuretic, and diuretics 
are also widely prescribed in general practice:in 1981 an esti-
mated three million prescriptions were provided in The Nether-
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lands, half of which to patients over sixty-five3. The pharma-
codynamics (effects) of diuretics can be studied quantitatively 
with several parameters, in observations without much in-
convenience for the patients. For these reasons diuretics were 
chosen as the object of the study. 
The clinical problems encountered with diuretics are mostly 
minor and certainly far less frequent than the problem of 
appraising the biochemical "deviations of the mean" caused by 
diuretics. Clinically manifest problems can be exaggerated 
effect or, on the contrary, diuretic resistance, occasionally 
diabetes mellitus requiring therapy or an attack of gout. 
Especially in the elderly, strong-acting diuretics can lead to 
a brisk diuresis causing hypotension, urinary incontinence, 
acute urine retention and interference with social activities. 
The biochemical abnormalities include hypokalaemia and hyper-
uricaemia. 
3. What to study about diuretics in the elderly and which 
diuretic to choose 
Questions confronting a pharmacologically interested clinician 
are: what are the effects of age, long-term treatment and 
disease on pharmacokinetics? What are the effects of age, long-
term treatment and disease on pharmacodynamics? To what extent 
and why is the pharmacological behaviour of a diuretic in aged, 
diseased, chronically treated people different from that in the 
standard healthy volunteer? 
Can therapy be individualized on the basis of these differen-
ces? 
At the time we were planning our studies, tienilic acid (TA) 
was newly introduced in the USA as a thiazide-like diuretic. 
Extensive experience with the drug existed only in France. 
A particular aspect of TA is its uricosuric activity. The bio-
chemical phenomenon of hyperuricaemia and the clinical problem 
of an attack of secondary gout in diuretic-treated patients 
or a need for diuretic treatment in a patient with primary 
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hyperuricaemia or gout, prompted our decision to start studies 
with tienilic acid. Given the possibility that uric acid repre-
sents an independent cardiovascular risk factor, we assessed TA 
as a promising new drug with the potential of wide-scale use 
also in the elderly. Finally, the lowering effect of TA on 
plasma uric acid (by increasing renal excretion) was an extra 
parameter of effect and patient compliance. We developed a 
method for determination of TA in plasma and urine. We did 
studies in healthy volunteers and obtained data suggesting that 
hyperuricaemic patients respond differently to TA. We were 
unable to do chronic studies in elderly and hyperuricaemic 
patients because TA was suddenly withdrawn from the market, 
suspected of causing liver damage. The evidence on which this 
FDA decision was based has not yet been published properly. 
After this adversity we had to change the subject but not the 
objective of our study: we chose to study furosemide (F), 
in The Netherlands the drug by far most widely prescribed to 
the elderly3 . 
We set up a determination method of F. After a review of the 
extensive F studies in healthy volunteers reported in the 
literature, we did not duplicate these studies but started 
with studies in the elderly. Although we planned studies in 
healthy aged volunteers as well as in geriatric patients, an 
unfinished debate with the local "committee on experimental 
research in human beings" made us study only old patients 
already using F. 
For practical reasons we had to study the patients in an in-
patient situation: partly in the University Hospital (St. 
Radboud Nijmegen) and partly in a nursing home (Irene Pavil-
joen H.Landstichting). Patients who had a very complicated 
clinical picture or were bed-ridden were excluded. We also 
studied the problem of F resistance in the nephrotic syndrome 
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because we were alerted by the studies of Green and Mirkin 
that this resistance could be due to protein binding of F in the 
renal tubule. If that explanation was correct, administration 
of a displacing other drug would increase the diuretic effect. 
3 
Sulphamethizole could be a suitable displacing drug in the 
tubular lumen, as it is rapidly excreted in urine in large 
quantities. It is known that sulphonamides displace F from 
its plasma protein binding sites. 
PROBLEM STATEMENT 
The considerations described raise the following questions: 
a. regarding TA 
- how can we measure TA and possible TA metabolites in 
plasma as well as in urine? 
- what are the pharmacokinetics of TA in healthy volunteers? 
- what are the effects of TA on excretion of sodium and 
uric acid? 
- what is the relation between plasma or urinary levels 
of TA and effect in the individual? 
- are the dose-response curves of TA versus sodium excre-
tion within a group of volunteers comparable? 
- do differences exist in uricosuric effects of TA,depen-
dent on pre-existent plasma uric-acid level? 
- is the tubular secretion of TA saturable in the thera-
peutic dose range? 
b. regarding F 
- which factors determine the in-vitro degradation of F? 
- is it possible to develop a handling procedure for F, 
eliminating degradation problems? 
- how can we measure F and F-gluc especially in urine? 
- what are the pharmacokinetics of F in old patients on 
long-term F treatment? 
- what are the effects of F in old patients on long-term 
F treatment? 
- can causes of diuretic resistance be classified in a way 
providing guidelines to overcome the problem? 
- what is the relation between plasma or urinary levels 
of F and effect? 
- do differences exist in the pharmacokinetics and pharmacodyna-
mics of F in the above mentioned patients, if compared with 
data from the literature on healthy volunteers given F? 
- can advice about F dosage be given, taking into account both 
changes in F handling and impaired circulatory homoeostasis 
in old age? 
- how extensive is the protein binding of F under circumstances 
supposed to exist in the nephrotic syndrome in the thick as-
cending limb of Henle's loop? 
- is it possible in-vitro to displace F from its protein binding 
sites m urine with sulphamethizole and 
- if so, is the F effect in the nephrotic syndrome enhanced by 
concomitant sulphamethizole administration? 
Background data pertinent to the questions to be answered are 
presented and discussed m chapter II, III and IV of this thesis. 
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Chapter II 
DIURETICS 
2.1 Renal transport of sodium and chloride 
Renal mechanisms (normally) maintain the salt content of the 
extracellular compartment within normal limits. The kidney 
possesses a number of mechanisms for reabsorption of sodium 
(fig 2.1 and fig 2.2). At the moment twelve anatomically and 
functionally different sites are recognized (1,2). 
In the proximal tubule 6 0 to 70 percent of the glomerular fil-
trate is reabsorbed by a variety of transport processes, but 
the most important driving force seems to be Na -K -ATPase 
located at the basolateral membrane (3). 
The part of the glomerular filtrate that escapes reabsorption 
by the proximal tubule passes down through the hairpin-shaped 
loop of Henle into the medulla and papilla. 
The mechanisms of active chloride transport (4) in the thick 
ascending limb of Henle's loop (TALH) have recently been re-
studied (5). It appears that primary active chloride transport 
does not account for NaCl reabsorption in the TALH. The trans-
port of chloride is coupled to sodium fluxes generated by the 
Na -K -ATPase located at the basolateral membrane. Transport 
across the luminal membrane is therefore secondarily active 
transport. The transport mechanisms for the coupling of sodium 
and chloride fluxes differ in the nammalian cortical and medul-
lary TALH. In the medullary TALH, sodium and chloride fluxes 
appear to be directly coupled via a NaCL co-transport system, 
which can be inhibited by furosemide (F). The mammalian cor-
tical TALH probably possesses multiple transport systems for 
sodium and chloride: a iNa -IK -2C1 co-transport, a NaCl co-
transport and two parallel antiport mechanisms acting syn-
chronously: a Na /H and a Cl /HCO3 exchange, all of which 
can also be inhibited by F. 
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This transport of solute into the medullary interstitium makes 
this compartment hypertonic, whereas the luminal fluid becomes 
hypotonic. This is possible because the TALH is impervious to 
water. This elegant mechanism results in the formation of a 
large volume of dilute fluid which, in the absence of anti­
diuretic hormone (ADH), passes on (6) 
NaHCOa g l o m e r u l u s 
w a t e r ( isosmotic ) \^_^/fy^ h y p o s m o t c н * 
organic 
a c i d φ 
pathway 
NaCI 
w a t e r ( ι s o s m o t i c ) 
isosmotic 
h y p e r o s m o t i c 
hyperosmotK 
Figure 2.1 Simplified diagram of the transport processes dis­
cussed in chapter II. The numbers indicate the sub­
sequent segments of the nephron (1,2) . 
through the nephron and enables the body to get rid of water 
in excess of solute (dilution ability, expressed as free water 
production CH2O)· I n ^ 6 Presence of ADH, however, water passes 
from the collecting duct into the medullary interstitium, and 
the concentration of the residual urine in the ducts becomes 
hypertonic. In this way the body gets rid of solute in excess 
of water (concentration ability, expressed as free water re-
absorption Тц
 0 ) . 
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Fig 2.2 Scheme of sodium reabsorption in the nephron. The 
total length of each arrow indicates the relative 
magnitude of the transport processes. The width 
of the funnel indicates the fraction of filtrated 
sodium that is still present in each segment. 
Blockade of sodium chloride transport in the medullary and cor-
tical TALH therefore leads to restriction of both concentrating 
and diluting ability (regardless of the presence or absence of 
ADH) because the medullary interstitium is made less hyper-
tonic and the tubular fluid is not diluted. The role of urea 
in establishing hypertonicity is not discussed (7). Active 
sodium reabsorption continues in the distal cortical parts of 
the nephron. In the absence of ADII this process further dilutes 
tubular fluid. Because sodium is here reabsorbed beyond the site 
where it can contribute to tonicity of the medullary intersti-
tium, blockade in this region reduces diluting ability without 
affecting concentrating ability. Reabsorption of sodium in the 
distal tubule and collecting duct is to some extent subject to 
the influence of aldosterone. Potassium and hydrogen are secre-
ted in the urine in exchange for sodium. 
In man, some 15 percent of nephrons have juxtamedullary glomeru-
li and long loops of Henle that dip down into the medulla. The 
suggestion is that juxta-medullary nephrons are especially adap-
ted to sodium conservation, whereas those supplied by outer cor-
8 
tical glomeruli excrete a larger fraction of filtrated sodium 
(8). Auto-regulating mechanisms seem to be able to redistribute 
renal blood flow from the outer cortex to the juxta-medullary 
nephrons, in association with a diminished effective circulating 
volume. This shift can be influenced by drugs, for instance by 
F and by indomethacin. Two more phenomena have to be discussed. 
There is a circadian variation in urinary volume and sodium ex-
cretion, with lower urine flow rates during the night and higher 
flow rates at midday and in the evening (8,9,10). Another firmly 
established mechanism in maintenance of sodium homoeostasis is 
glomerulotubular balance, i.e. the parallel and more or less 
proportional adjustment in absolute proximal sodium reabsorption 
that takes place in response to variation in glomular filtration 
rate. This seems to depend on the sodium (-chloride) concentra-
tion at the luminal site of the macula densa cells in the distal 
convoluted tubule (11). F can inhibit this feed-back system (12). 
2.2 Renal transport of uric acid 
Insight into the renal handling of uric acid in man is largely 
hypothethical (13). Uric acid is the final degradation product 
in the metabolism of purine compounds. It is poorly soluble in 
serum (0.41 mmol/1 m serum at pH 7.4) and in acidic urine 
(0.9 mmol/1 in urine at pH 5), the solubility in urine increases 
with rising pH (12 mmol/1 in urine at pH 7). Urate is freely 
filtrable through the glomerular capillaries. In the renal 
tubule a very complex process of reabsorption of filtered urate, 
secretion,and reabsorption of secreted urate must take place. 
These conclusions are based mainly on the results of indirect 
studies with pharmacological agents: probenecid (thought to in-
hibit mainly reabsorption of urate) and pyrazmoic acid (thought 
to inhibit urate secretion). The current model of urate handling 
in man (fig 2.3) postulates free filtration in the glomeruli 
and net reabsorption in the first ("early") part of the proximal 
convoluted tubule (S·)), followed by net secretion in the late 
proximal convoluted tubule and cortical early straight tubule 
(S2). Net reabsorption again occurs in the distal part of the 
proximal tubule (83). Among the factors that affect the renal 
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handling of urate in an individual, the extracellular fluid 
volume is one of the dominant influences. 
Figure 2 . 3 Scheme of urate 
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2.3 Site of action and mode of action of diuretics 
Diuretics are among the most powerful pharmacological tools de­
veloped to be used by the clinician in the treatment of patients. 
Diuretics are used in the (symptomatic) treatment of patients 
with congestive heart failure (CHF), hypertension, oedema asso­
ciated with cirrhosis of the liver, and oedema in the nephrotic 
syndrome (14,15). Other indications for loop diuretics can be 
hypercalcaemia and for thiazide-like diuretics hypercalciuria 
and nephrogenic diabetes insipidus (by impairment of diluting 
capacity?). It is important to appreciate that the development 
of oedema is a manifestation of an underlying disease with 
diminished effective blood volume. Natriuretic drugs for oral 
administration first became available in the late Fifties (16). 
Some people even refer to the era ВС (before chlorothiazide, 
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Diuril ) and the period AD (after Diunl®) . Aoart fron this, stu-
dies with diuretics have made a major contribution to our under-
standing of normal renal physiology. The kidneys regulate extra-
cellular volume to achieve a volume appropriate to meet the meta-
bolic requirements of the organism. The kidneys respond to a 
diminished effective blood volume by reabsorption of excessive 
sodium and water; the mechanisms of increased salt retention 
have been elucidated only in part, as will be discussed in the 
section on influences of CHF on sodium homoeostasis. 
For sake of convenience, diuretics are divided into six groups: 
- osmotic diuretics (like Mannitol) 
- carbonic anhydrase inhibitors (like acetazolamide) 
- organomercurials (like mersalyl) 
- high-ceiling or loop diuretics (like furosemide) 
- sulphonamide diuretics (including both thiazide and non-
thiazide drugs) 
- potassium-sparing diuretics (like spironolactone, amiloride). 
The osmotic and organomercunal diuretics are not manageable 
orally and the carbonic anhydrase inhibitors show tachyphylaxis; 
three useful classes of diuretics thus remain (17,18,19,?0). 
- The high-ceiling diuretics (ethacrynic acid, furosemide, bume-
tanide, piretanide and several research drugs) inhibit (so-
dium-) chloride transport at the luminal surface of the entire 
thick ascending limb of Henle's loop (21,22,23,24,25). Their 
effect on the proximal tubule is of minimal clinical impor-
tance. The relevance of the changes induced by these drugs 
to intrarenal haemodynamics (26) is not certain. The loop 
diuretics are very potent drugs inducing a fractional sodiun 
clearance amounting to as much as 20 to 25 percent (i.e. 20 to 
25 percent of the filtered load of sodium). 
- Thiazides and thiazide-like diuretics (e.g. chlorothiazide, 
hydrochlorothiazide, bendroflumethiazide, chlorthalidone) act 
in the distal tubule. Perfusion studies suggest that most of 
these drugs inhibit sodium transport via a luminal site of 
action. They are much less potent than the loop agents and 
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therefore useful in treating milder sodium-retaining states. 
These drugs can induce a fractional sodium clearance of up 
to ten percent. It must be stressed, however, that potency 
per se does not determine total effect. Due to their longer 
duration of action the total effect of thiazides can even 
exceed the effect of the short-acting loop diuretics. The 
na^or difference between the various thiazide preparations 
is their duration of action. 
Thiazides, too, have some effect on proximal tubule transport 
processes in isolated organ preparations, but in concentration 
ranges not normally attained in vivo. Tiemlic acid (ticry-
nafen) is a thiazide-like diuretic with special characteris-
tics, which will be discussed separately. 
- The potassium-sparing diuretics can be divided into two groups: 
aldosterone antagonists (spironolactone, canrenoate) and al-
dosterone-independent potassium-sparing diuretics (amilonde, 
triamterene). 
Accordingly, the diuretic and antikaliuretic effect of spiro-
nolactone depends on the presence of aldosterone. This is 
probably an antiluminal membrane-bound effect, also taking 
place in the distal convoluted tubule and possibly in the 
cortical collecting duct (20). Triamterene and amilonde 
inhibit potassium secretion also in the absence of aldosterone 
and have an earlier onset of action. Amiloride probably re-
duces sodium permeability at the luminal membrane (27), 
whereas triamterene is supposed to act from the peritubular 
space (17). Potassium-sparing diuretics are very weak 
diuretics if used alone; they are useful only in combination 
with thiazide-like or loop diuretics. They induce fractional 
sodium clearance of at best a few percent, and only if there 
is no circulatory need for the kidney to retain sodium. 
Like side effects of drugs m general, the complications of diu-
retic therapy (20,28) can be divided into three groups: 
- caused by overdose : volume depletion is a common complicatici 
of diuretic use, but especially in patients who are unable 
to replace urinary losses because of nausea, vomiting and 
dxarrhoea; ototoxicity is dose-related, too. 
12 
- understandable in view of the pharmacological way of action, 
too, but already occurring at adequate dosage: volume con-
traction, potassium depletion, metabolic alkalosis, hypo-
natraemia, hypercalcaemia, hyperuricaemia, impaired glucose 
tolerance. 
- idiosyncratic side effects peculiar to an individual patient: 
hyperglycaemia, secondary gout, hypersensitivity reactions 
such as exanthema and anaphylaxis. 
The incidence of side effects of F in hospitalized patients has 
been reported from Boston and Scotland. The data are generally 
reassuring, since serious toxicity was unusual. In the Boston 
Collaborative Drug Surveillance Program (29) the incidence of 
side effects was 10.1% (in 2367 patients): 
- 4.6% signs of intravascular volume depletion (indicated by a 
rise in BUN), especially in patients who received other diu-
retics prior to or during F treatment. 
- 3.6% "clinically important" hypokalaemia. 
- 1.5% other metabolic or electrolyte disorders (hyperuricaemia, 
hyperglycaemia, hypernatraemia, hypochloraemia). 
- 0.4% other adverse reactions, e.g. skin rash. 
- in 14 instances the side effects of F were considered to be 
life-threatening, but only in two cases (0.08%) was F judged 
to have contributed to the patient's death. 
In the Scottish study of 585 patients (30) more stringent cri-
teria of biochemical normality were defined, leading to dif-
ferent figures but the same trends: 
- 14.5% volume depletion (based on BUN rise) 
- 9.2% hyperuricaemia 
- 3.6% hypokalaemia 
- clinically: an attack of gout occurred in two patients, 
confusion in two, rash in one, glucosuria on one, thrombo-
cytopenia in one patient. 
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Figure 2.4 Chemical structure of tiemlic acid and ethacrynic 
acid. 
Tiemlic acid (TA), (2, 3-dichloro-4- (2-thienylcarbonyl-) phe-
noxy) acetic acid was found to be an effective diuretic and 
antihypertensive drug with uricosuric activity in several ani­
mal species (31) as well as in man (32). The uricosuric pro­
perties of TA are welcome in the treatment of patients with 
gout who are also in need of diuretic treatment for hyperten­
sion or congestive heart failure, or in the treatment of 
patients who develop secondary gout while using another diure­
tic. Apart from this, the possibility has to be considered 
that an increased uric acid level may be an independent minor 
risk factor in the development of cardiovascular diseases (33) 
In that case a hypouricaemic effect of a hypotensive drug is 
an essential advantage over the hyperuncaemia caused by anti­
hypertensive medication with other diuretics. 
On the basis of its dichlorophenoxy acetic acid skeleton, TA 
appears to be related to ethacrynic acid. But there are im­
portant differences: chemically, TA is non-reactive with cys­
teine, whereas the cysteine ethacrynic acid complex is probably 
the active form of ethacrynic acid (34) . Pharmacologically, the 
site of saliuretic TA action is not the TALH but the cortical 
diluting segment of the distal tubule. The observation that re­
duction of natriuretic activity occurred under conditions in 
which TA excretion was inhibited, led to the hypothesis that 
its site of natriuretic action is at the luminal site of the 
renal tubule cells (35,36). The uricosuric activity of TA m -
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volves other parts of the nephron and other transport mecha-
nisms: pyrazinoate inhibits the uricosuric activity of TA, but 
not the natriuretic activity (37). This is in accordance with 
the hypothesis that uric acid transport processes take place in 
the proximal tubule and not in the cortical diluting segment 
of the distal tubule (as discussed in section 2.2). 
The side effects initially encountered and reported with TA 
were the expected extension of its diuretic action and also 
precipitation of gouty attacks, as seen with every uricosuric 
drug (38). Later on, reports about a dangerous interaction with 
oral anticoagulants (39) and acute renal failure appeared in 
the literature (41). In January 1980 the product licence was 
suspended at once in the USA (a decision followed by most other 
countries) because TA was suspected of causing potentially 
fatal hepatitis. Toxicological studies of hepatotoxicity are 
controversial (42,43). No final conclusive report regarding the 
alleged hepatotoxicity connected with chronic TA medication has 
so far been published. Extensive information on TA can be found 
in the Medical Intelligence section of NEJM (44) and in special 
supplements of Nephron (45) and Postgraduate Medical Journal 
(46). 
2.5 Furosemide 
Figure 2.5 Chemical structure of 
furosemide. The dotted 
line indicates the 
first step in decom-
position (acid hydro-
lysis, chapter VI). 
In the Sixties, furosemide (F), 4 chloro-N-(-2-furfuryl-)5-
sulphamoylanthranilic acid was found to be a very effective diu-
retic (47,48). Although F is chemically related to the thia-
zides, its natriuretic action resembles that of ethacrynic acid. 
It exerts its action by inhibiting sodium chloride transport 
at the luminal site of the TALH (21). Probenecid inhibits renal 
secretion of F and delays its natriuretic effect: the best 
i o ^ 
Furosemide 
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correlation between dose and effect is obtained when the amount 
of F excreted in the urine is used as the "dose". F is a weak 
acid with a pKa of 3.8, implying nearly total ionization at 
tubular pH 6-7. For many drugs transport to their receptors 
requires the unionized state, and consequently attempts have 
been made to influence the degree of ionization of F by chan-
ging the pH of blood (pH range 7.2 - 7.6) and urine (pH range 
5-9) in order to enhance F concentration in the biophase. This 
had no effect on the saliuretic activity of F (52) but, because 
the pH of urine is largely determined in the distal tubule (53), 
pH changes achieved in the TALH were probably minimal. 
F is largely bound to plasma protein (especially albumin) and 
secreted via the common carrier-mediated organic acid pathway 
of the proximal tubule. The protein binding of F in plasma has 
been studied by Prandota, among others; he describes two classes 
of binding sites involving hydrophobic, ionic and hydrogen 
forces. Several drugs reduce F protein binding, e.g. acetazola-
mide, diazoxide, phenylbutazone, sulphisoxazole and tolbutamide 
(54). At normal plasma albumin concentration and clinically 
attained F concentrations (1-12 vg/ml) there is a protein binding 
of about 98%. The metabolism of F is controversial: some authors 
describe 4-chloro-5-sulphamoylanthranilic acid (CSA) as a meta-
bolite, others are unable to trace this substance in biological 
samples; the extent of glucuronidation is also uncertain, es-
pecially during chronic treatment (55) . Photodegradation of F 
and ex-vivo degradation of F glucuronides at least partly ex-
plain the differences in published data on metabolism (as will 
be discussed in chapter VI]) . Adverse reactions to F consist 
mainly of an extension of its pharmacological activity. The most 
common side effects are hypovolaemia, hyperuricaemia and hypo-
kalaemia (29,30), as discussed in section 2.3. 
The clinical pharmacokinetics and pharmacodynamics of F were 
extensively reviewed in 1979 by Cutler & Blair (56) and by 
Benet (57). A summary of these data is given in the introduction 
of chapter Vila. 
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CHAPTER III 
SOME FACTORS INFLUENCING DRUG RESPONSE 
3.1 Influence of age on pharmacokinetics and pharmacodynamics 
"ageing is not a disease and as such is not treatable by medi-
caments" 
WHO Technical group,etc. 
The elderly receive more drugs than the young. However, they 
gain less from treatment with drugs than do younger patients. 
The incidence of adverse drug reactions increases about seven-
fold in old age and therefore the possible risk of adverse 
reactions should overshadow all other considerations when pres-
cribing for the elderly. This increased incidence of side ef-
fects could be a result of incorrect clinical assessment, mul-
tiple prescribing, poor patient compliance, inadequate super-
vision of long-term medication, altered drug handling, increased 
organ sensitivity with age and impairment of homoeostatic recha-
nisms (2). The need for special prudence regarding drug therapy 
m the elderly is stressed again and again (1). Many recent 
reviews are available (1-13). Important (although sometimes 
subtle) physiological and psychological changes occur with 
'normal' ageing. Added to these changes are those caused by 
overt diseases which, manifold and partly interrelated, are more 
prevalent in the elderly. Such factors complicate pharmacothera-
py. Only a few drugs have been studied m the elderly, and most 
pharmacokinetic studies in the elderly have been conducted after 
single dose administration. Some pharmacokinetic differences 
have been documented and the findings tend to be consistent with 
age-related changes in body composition, protein binding, hepa-
tic metabolism and renal excretion. The changes in pharmacoki-
netics and pharmacodynamics are depicted in figure 1 of chapter 
Vila. The key elements of this diagram are briefly discussed 
(although correlations between age and responses to drugs are 
neither inevitable nor in their nature predictable). 
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Pharmacokinetics 
- Absorption; most drugs are absorbed by passive diffusion along 
a concentration gradient of non-ionized substance, and the 
rate and amount of these drugs absorbed is unchanged. Active 
transport systems on the other hand are affected by ageing, 
and reduced absorption of iron, calcium and certain vitamins 
has indeed been demonstrated. 
- Distribution; after absorption drugs are distributed over the 
body. The amount and pattern of this distribution depend on 
the physico-chemical characteristics of the drug in relation 
to the physico-chemical characteristics of the body, and some-
times on active transport processes. The composition of the 
body changes with age: body weight, body water and muscle mass 
decrease, body fat content increases (on average in men from 
15 to 36%, in women from 33 to 45%). The effect of these chan-
ges is that water-soluble drugs reach higher blood levels in 
a smaller distribution volume. Lipid-soluble drugs, however, 
reach lower blood levels in a larger distribution volume but 
have an increased serum half-life, even if the total body 
clearance remains unchanged. 
- Plasma proteins (especially albumin) are a very important drug 
reservoir. Only the free (unbound) fraction of a drug is phar-
macologically active, and subject to distribution into the 
tissues, metabolism and excretion (generally speaking). The 
serum albumin level decreases with age; this lower level of 
albumin can lead to an increased free fraction of one drug 
(14,15) and enhances the risk of drug interactions. 
- The liver is the most important organ for the metabolism of 
drugs, and available data on drug metabolism mainly focus 
on the liver. The metabolic potential of the liver is deter-
mined by hepatic blood flow and by qualities and quantities 
of drug-metabolizing enzymes. Many substances enlarge the 
amount of these enzymes; this process is called induction. 
The liver is supplied with blood from the hepatic artery and 
the portal vein; drug extraction by the liver from the portal 
circulation is called pre-systemic or first-pass elimination. 
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The hepatic blood flow, portal blood flow included, declines 
with age and there are sufficient data on first-pass extrac­
tion to suggest that any drug with a high extraction ratio 
will to a greater extent reach the systemic circulation and be 
eliminated more slowly in the elderly. Drugs are metabolized 
in various ways (16): by phase I reactions (oxidation, reduc­
tion, hydrolysis) and by phase II reactions (conjugations). 
In the elderly the capacity for oxidation of some drugs is 
reduced, while for others it is unchanged. Hydrolysis and 
reduction are unchanged so far as we know, and no reports 
mention a reduction in conjugation reactions. Finally it has 
been shown that induction of hepatic microsomal enzymes by 
smoking, caffeine, alcohol or a high-protein diet is reduced 
in old age (17). In conclusion: the hepatic metabolism of 
drugs is sometimes reduced in old age. 
- It is now well established that the renal excretion of drugs 
by glomerular filtration and tubular secretion decreases with 
age, even though there may be no clinical evidence of renal 
failure. Because the muscle mass available in the elderly 
to produce creatinine is reduced, the glomerular filtration 
rate (GFR) must be strongly reduced before the serum creatini­
ne level rises above "normal" (18). The decrease in tubular 
secretion capacity parallels the decrease in GFR (19). The 
decrease in renal function is probably the more important 
factor responsible for altered drug levels in the elderly. 
The age-related decrease in GFR after the fourth decade is 
estimated to be about 0.8 ml/min per year (19). Rowe calcu­
lated an average annual decline in GFR of 0.0 3 ml χ bodyweight 
in kg χ age in years (20). 
All these factors together (unchanged absorption, possibly im­
paired protein binding, slightly decreased metabolism and de­
creased renal excretion) tend to lead to higher (free) plasma 
levels (e.g. 21). 
A complicating factor is the polypharmacy often encountered in 
the elderly: absorption, plasma protein binding, metabolism 
and renal tubular secretion can be profoundly changed by drug 
interactions. 
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Pharmacodynamics 
Most drugs interact with specific receptors to induce their 
effects. The response to a drug is a reflection firstly of the 
drug's concentration at its site of action, secondly of the 
ability of a given amount of drug to affect the receptor so as 
to produce a "stimulus" and thirdly of the translation of the 
effect on the receptor to a responsive tissue or tissue system, 
i.e. stimulus-effect relationship. 
Apart from lower drug concentrations, decreases in response may 
result specifically fron: 
- an increase in the threshold of a receptor to the effects 
of a drug 
- a decrease in number or affinity of receptor sites or a chan-
ged stimulus-effect relationship, such as a decrease in avai-
lable enzymes that help translate the effect of a drug 
- structural changes in the tissue itself which could be rate-
limiting with respect to its response, and finally 
- an alteration in the interrelationship of various organ sys-
tems, as it changes with age or in response to the primary 
effect of the drug. 
Multiple diseases and environmental factors such as nutritional 
status may also alter end-organ sensitivity, of course it is 
hardly possible to study in man which exact step in the above 
described sequence of events is changed in the elderly. There 
is suggestive evidence for a few drugs that the sensitivity 
to a given concentration is altered. Enhanced sensitivity exists 
to several drugs acting on the cerebral nervous system (e.g. 
nitrazepam (22)) and to warfarin (23). On the other hand, aged 
patients are less sensitive to beta-adrenergic stimulation and 
blockade at the cellular level (24,25,26). 
3.2 Effect of long-term treatment 
Most drugs are not used ine identically but over a longer period 
of time; chronic medication is often indicated. During chronic 
treatment the problem of tolerance can develop. Tolerance is a 
very general phenomenon observed with numerous substances, and 
it involves several independent mechanisms. Tolerance may be 
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acquired to the effects of many drugs. When this occurs, cross-
tolerance may develop to the effects of pharmacologically related 
drugs, particularly those acting at the same receptor sites. 
Sometimes tolerance does not develop to all effects of a drug. 
When only tolerance to the desired effects emerges, dose rela-
ted side effects occur more often due to the larger doses needed 
to maintain the desired drug effect; the so-called therapeutic 
index of the drug decreases. 
On the other hand there are also examples of tolerance to the 
undesired effects of a drug, resulting in an increased thera-
peutic index. The three mechanisms involved in the development 
of tolerance are: 
- pharmacokinetic tolerance, resulting from changes in the phar-
macokinetic properties of the agent in the organism, so that 
reduced concentrations are present at the sites of drug ac-
tion. Both desired and undesired effects of the drug are 
reduced. The most common mechanism is an increased rate of 
metabolism. Several drugs can induce their own metabolism by 
induction of microsomal enzyme activity: e.g. phenylbutazone, 
tolbutamide, chlorpromazine, phénobarbital, carbamazepine, 
meprobamate; benzene, DDT and ethanol are also auto-inducers 
(27) . 
- pharmacodynamic tolerance, involving changes in the receptors 
or in the stimulus-effect relationship. The response to a drug 
diminishes although its concentration remains the same as 
before. The problem has long been recognized for hypnotics 
and opioids. Receptors are not only the determinants of acute 
regulation of physiological and biochemical function, but also 
are themselves subject to more chronic regulation and homoeo-
static control: the number and affinity of receptors can 
change. For example: continued stimulation of various types 
of cells with beta-adrenergic agonists results in a state of 
desensitization (down-regulation). This may involve alteration 
of the receptor or alteration of the pathway distal to the 
receptor itself. Supersensitivity (up-regulation) to receptor 
agonists is also frequently observed after reduction of the 
chronic level of receptor blockade. Situations of this type 
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can result from long-term administration of beta-antagonists 
such as propranolol (28) . The synthesis of additional (dopa-
mine D2?) receptors during chronic treatment with neuroleptics 
is supposed to lead to the development of tardive dyskinesia 
(29,30). A decrease in (alpha-2, serotonin-2 or beta-adrener-
gic?) receptors seems to play a role in the desired effects 
of antidepressant drugs (28,31,32). 
- Counterregulator^ mechanisms may also play a role in the 
development of tolerance to a drug. Chronic use of stimulant 
laxatives for instance can induce hypokalaemia; hypokalaemia 
reduces the excitability of smooth-muscle cells m the bowel, 
thereby reducing the effect of the laxative (33). Another 
example is that the use of diuretics frequently leads to volume 
contraction; as a result, more solute is reabsorbed in the 
proximal tubule and thus the maximal effect of diuretics di-
minishes (34,35) . 
Apart from all these pharmacological considerations the pro-
gressive nature of many chronic diseases in man must be borne 
in mind as an inevitable reality, ultimately leading to irre-
versible and untreatable losses. 
3.3 Heart failure and its influence on sodium homoeostasis 
and on disposition and effect of diuretics 
Heart failure 
In view of the different disease states in the patient studies 
to be described in chapter Vllb, the consequences of both 
chronic cor pulmonale (right ventricular failure) and chronic 
left ventricular failure must be briefly discussed. 
Cor pulmonale (36) , hypertrophy of the right ventricle resulting 
from diseases affecting the function and structure of the lungs, 
has a natural history with stable neriods and exacerbations. In 
the acute attack the signs of increased jugular venous pressure, 
hepatomegaly and often gross peripheral oedema suggest the diag-
nosis of congestive heart failure (CHF). However, it is ques-
tionable whether the term failure is correct, for in this state 
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cardiac output can be normal or even increased at rest (37,38). 
Other authors postulate a decrease in cardiac output once oedema 
appears, as Heinemann does in a review (39). The outlook in such 
patients is grave, and two-thirds die within five years (37). 
In the absence of ischaemic or valvular heart disease, few 
patients with cor pulmonale have been shown to have abnormal left 
ventricular function too (36). Renal blood flow diminishes once 
oedema develops, the glomerular filtration rate may be depressed 
and plasma renin activity and aldosterone levels increased. 
In left ventricular failure (apart from rare cases of 
high-output failure as in beri-beri) cardiac output decreases 
progressively. The clinical picture comprises respiratory dis-
tress (exertional dyspnoea, orthopnoea, paroxysmal nocturnal 
dyspnoea, dyspnoea at rest, pulmonary oedema), fatigue, weak-
ness, nocturia and, especially in the elderly, cerebral symptoms 
like confusion, anxiety, insomnia or nightmares. Physical fin-
dings include pulmonary rales, increased jugular pressure, con-
gestive hepatomegaly and, after substantial gain of extracellu-
lar fluid volume, oedema (40). As in cor pulmonale, the letha-
lity of the disease is high: five years after the onset of CHF 
about half the patients have died (41). 
Sodium_homoeostasi^ 
Total renal blood flow diminishes as the cardiac output de-
creases. This results in changes in the several sodium excre-
tion mechanisms (42,43,44). 
- From experiments in the dog it has been concluded that, in 
connection with reduced renal blood flow, intrarenal redis-
tribution of this flow occurs with reduction of outer cor-
tical blood flow and increased inner cortical and outer medul-
lary flow. The mechanism of this redistribution has not been 
elucidated; it is ascribed to neurogenic, catecholamine-
mediated, angiotensin-mediated mechanisms, among others (45). 
The filtered load of sodium is determined by glomerular fil-
tration rate (GFR) and plasma sodium concentration. Net fil-
tration rate in a simplified form is determined by the diffe-
rence between hydrostatic and oncotic pressure; hydrostatic 
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pressure is determined by renal biood flow and renal vascular 
resistance (RVR); oncotic pressure depends on serum albumin 
and filtration fraction (the ratio of GFR to renal blood flow). 
In left ventricular failure, renal blood flow diminishes but 
RVR increases, probably by vasoconstriction of the postglomeru-
lar arteriole. With the rise in RVR the filtration fraction also 
increases so that the oncotic pressure rises; this, combined 
with the lowered postglomerular capillary hydrostatic pres-
sure, facilitates reabsorption of sodium (46,47). 
- Aldosterone levels are normal or increased in pre-treatment 
patients with CHF (48), this is appropriate in relation to the 
stimuli mentioned above, but inappropriate in the setting of 
gross expansion of extracellular fluid volume. Aldosterone 
levels initially fall during diuretic treatment and later rise 
to high values as "dry body weight" is attained; the fluctu-
ations of PRA parallel those of plasma aldosterone. With re-
gard to the aged patients studied by us it merits mentioning 
that hypertension often precedes CHF and that in hypertensive 
subjects the arterial baroreceptor sensitivity as well as the 
responsiveness of the renin-angiotensine system decreases with 
age (49) . 
- De Wardener postulates a still ill-defined "third factor" 
influencing sodium excretion (50) . In the opinion of Farley 
and Martino (34), excessive proximal sodium reabsorption (un-
explained by GFR or aldosterone changes) plays a role in the 
pathogenesis of sodium-retaining states. They estimated proxi-
mal sodium reabsorption, in normal subjects and in patients 
with cirrhosis and ascites, by blocking distal tubular sites 
with diuretic agents (ethacrynic acid and chlorothiazide). 
In normal subjects 69% of the sodium load was reabsorbed pro-
ximally if supine (76% if upright); in their volume-expanded 
cirrhotic supine patients this figure was 76%. 
Bennett et al (51) studied proximal tubular reabsorption in 
patients with CHF both before and after standard diuretic treat-
ment. Tubular blockade was effected with ethacrynic acid— 
chlorothiazide-triamterene. Before treatment 68% of the 
sodium load was reabsorbed proximally, after attainment of 
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dry weight this was 85%. Later, the same group using the same 
technique reported a proximal sodium reabsorption of 58% in 
normal subjects (46). 
To summarize: 
The mechanisms contributing to increased renal tubular reabsorp-
tion of sodium in CHF are thought to be: altered physical forces 
in peritubular capillaries (oncotic pressure up, hydrostatic 
pressure down), redistribution of renal blood flow, activation 
of the renm-angiotensin-aldosterone system, a lack of natri-
uretic hormone (?), changes in intrarenal hormones (?), stimu-
lation of the sympathetic nervous system and perhaps even more 
mechanisms (44). 
Disposition of_diuretics_in CHF 
In three of seven patients with CHF studied by Beermann and 
Groschinsky-Gnnd (52), the absorption of hydrochlorothiazide 
was reduced to approximately half that seen in healthy volun-
teers, while the renal clearance of the drug was markedly re-
duced in all patients. Brater (53) found no difference in oral 
bioavailability of F between patients with CHF and normal 
volunteers; renal F clearance correlated with renal function, 
which in turn correlated with left ventricular ejection frac-
tion. On the other hand a striking case history of F malabsorp-
tion has been published (54) as well as a study reporting no 
changes in F pharmacokinetics in CHF patients (55). In a study 
of Andreasen and Mikkelsen (56) the excretion of F-gluc after 
intravenous injection of 40 mg F was 0.8 mg in healthy volunteers 
and previously untreated CHF patients, but 6.7 mg in patients 
who had used F for more than six months. These scattered data 
allow no final conclusions regarding the disposition of diuretic 
drugs m CHF. 
Influence of_CHF_on effects of_diuretics_and_vi:ce versa 
The effect of a given F dose was reported to be less in CHF 
patients than in healthy controls; according to Brater this 
is to be explained by a shift to the right in the dose-response 
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curve (57). This decline in effectiveness was partly prevented 
(in another study) by additional therapy with hydralazine (58). 
Initial F therapy is reported to reduce only preload without 
changing cardiac output (59). Chronic F treatment appears to 
increase stroke volume and to decrease pulmonary wedge pressure 
and systemic vascular resistance (the main determinant of after-
load (60)). In conclusion: CHF probably influences the effects 
of diuretics. 
3.4 Diuretic resistance in CHF 
The variability in the response to diuretics is a common clinical 
experience. Some subjects respond rapidly and vigorously to small 
oral doses of loop diuretics, whereas others require large intra-
venous doses to achieve diuresis; many factors contribute to 
this variability. Obviously, diuretic drug treatment cannot com-
pensate for excessive salt intake, for instance. Pharmacological 
factors can be divided into several groups: 
pharmacokinetic factors-pharmacodynamic factors-counterregula-
tory mechanisms and interactions. A proposal for a systematic 
approach to diuretic resistance is made at the end of this para-
graph. 
Pharmacokinetic aspects 
- Reduced absorption of diuretics in oedematous states has been 
described incidentally, and ascribed to an oedematous gas-
trointestinal tract. The study of Beermann, demonstrating 
decreased absorption of hydrochlorothiazide (52) has been 
summarized in the preceding paragraph. Odlind found in one 
patient 17% oral F bioavailability in the oedematous state 
and 75% in the oedema-free state (54) . Several authors found 
no difference in oral F bioavailability in CHF patients (55, 
61). Colestipol decreases the absorption of chlorothiazide 
(62). Cholestyramine decreases the absorption of hydrochloro-
thiazide (89). The most common cause of non-absorption, how-
ever, remains non-compliance! 
- The distribution volume (VD) of diuretics changes in hypo-
albuminaemic oedematous states. Many authors, including our-
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selves, find a much larger Vp of F in patients with low albu-
min levels. A larger Vp means lower total plasma levels on the 
same F dose, so that less F is available for tubular secretion 
to its luminal site of action (63,64,65,66). This is only part-
ly compensated by a small concomitant rise in unbound F (67) 
available for glomerular filtration. Consequently a decrease 
in peak effect has to be expected, together with a prolonga-
tion of plasma half-life. 
- The metabolism of diuretics can be a cause of resistance: most 
diuretics are only active as the unchanged molecule at the 
luminal site of the renal tubule; extensive extrarenal clea-
rance by biotransformation of the drug therefore leads to a 
decrease in effect. A wide range of extrarenal F clearance 
values is observed in normal volunteers (68) . Lambert and her 
co-workers (69) found that rats responding poorly to F injec-
tion had extensive F metabolism, and that inhibition of hepa-
tic F metabolism with chloramphenicol increased plasma half-
life, increased the excretion of unchanged F and enhanced F 
effects in the animals. This has not been tried in man, but 
it has been shown in one patient that chloramphenicol reduces 
the clearance of phenytoin and phénobarbital considerably 
(70) . 
- The renal excretion of diuretics is one of the main determi-
nants of their effect. Since most diuretics are highly pro-
tein-bound, this renal clearance takes place almost exclusi-
vely by tubular secretion. Resistance to a diuretic may occur 
if the disease state or other factors prevent the diuretic 
from reaching its site of action. For example: in kidney 
transplant patients with a poor response to F, renal F clea-
rance and also the ratio of renal F clearance to creatinine 
clearance was markedly less than in the responders (71). In a 
group of patients with hepatic cirrhosis, too, the 'poor res-
ponders' had the lowest renal F clearance (64). In azotaemia 
accumulated endogenous organic acids block the active trans-
port pathway for organic acid diuretics, thereby preventing 
access to their site of action (72). Probenecid slows the re-
nal excretion of F (73), which implies that the peak effect 
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of F is diminished. 
Pharmacodynamic as£ects 
The bioavailability of orally given F is 60-69%. Nevertheless, 
the total effect of an identical intravenous dose is the same 
(74,75,76), whereas the urinary recovery of an oral F dose is 
far less. Brater therefore concludes (77) that, in addition to 
the total amount of drug delivered into the urine, the time 
course of delivery affects total response. To date, very few 
studies have been carried out which assess all the pharmaco-
dynamic determinants of diuretic response. In CHF a shift to 
the right in dose-response curves has been described, also by 
Brater (57). In CHF and cirrhosis the tubular urine is virtually 
protein-free. In the nephrotic syndrome, however, considerable 
arrounts of albumin are present in the glomerular filtrate and 
tubular urinp.. It might be expected that, inside the renal 
tubule too, the effect of a drug is determined by the free 
(unbound) concentration of that drug. Green and Mirkin (78) 
reported experiments suggesting F protein binding (in the renal 
tubule, at the site of action) to be the cause of F resistance in 
the nephrotic syndrome. This matter will be discussed more amply 
in chapter VIII. Clear-cut "receptor adaptation" to long-term 
diuretic treatment has not been described. 
Counterregulatory mechanisms_and_interactionj3 
Most diuretics act at the TALH or cortical diluting sites of the 
distal nephron by inhibiting solute and water reabsorption. If 
only small amounts of urine are delivered to these segments 
(caused by a greatly decreased glomerular filtration rate or 
avid proximal tubular reabsorption), then no impressive effect 
of diuretics can be expected: a pre-receptor, up-stream, cause 
of diuretic resistance. On the other hand the solute retained 
in the lumen by loop diuretics can yet be reabsorbed in the more 
distal parts of the nephron: a down-stream cause of diuretic 
resistance. In that case the diminished effect can be augmented 
by combining loop diuretics with thiazides (79), aldosterone 
antagonists (80) or both (51). 
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Drug interactions can be the cause of a decreased effect of diu-
retics. A well-known but incompletely understood example is the 
decreased effect of diuretics if combined with non-steroid anti-
inflammatory drugs (NSAID) like indomethacin (81,82,83,84,85). 
Finally, strong-acting vasodilators like diazcxide or minoxidil 
reduce the effect of diuretics. 
The above considerations can lead to the following suggestions 
for diagnostic and therapeutic management in the case of diu-
retic resistance (except in pre terminal renal failure): 
- have complicating illnesses such as pulmonary embolism, pul-
monary infection, hyperthyroidism, endocarditis, bradycardia, 
alcohol abuse, cirrhosis, severe electrolyte imbalance or 
malignant effusions been excluded or treated? 
- does the patient keep the diet? Explain again or arrange 
supervision. 
- does the patient take the pills? Explain again or arrange 
supervision. 
- is absorption impaired? Try the same dose intravenously. 
- is the distribution volume enlarged or the metabolism increased? 
Unfortunately they cannot be detected easily or influenced 
safely in man. 
- is renal secretion impaired by another tubularly secreted 
drug? 
- is proximal sodium reabsorption increased considerably? In 
emergencies osmotic diuretics or carboanhydrase inhibitors 
can be used, in combination with more distally acting diure-
tics. In less dramatic circumstances a combination therapy 
including the new diuretic metolazone could be helpful: apart 
from acting at the cortical diluting site in the distal parts 
of the nephron it is claimed that this drug also has a carbo-
anhydrase independent effect on proximal sodium transport 
(86,87). 
- is the effect of the loop diuretic counteracted in the more 
distal part of the nephron? Measure the K/Na ratio, if this 
exceeds 1, add spironolactone (80). A combination therapy 
of loop diuretic, thiazide and potassium-sparing diuretic 
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should be able to overcome counteracting distal mechanisms. 
- does the patient ingest NSAID's (precribed by another doctor)? 
If at all possible, stop them; there are preliminary reports 
suggesting that sulindac does not have this antidiuretic 
effect (89). 
- the concept of urinary F protein binding and the possibility 
to displace F from its protein binding sites in urine will be 
discussed in chapter VIII. 
Some of these considerations are summarized in the table. 
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TABLE 4.1 DIURETIC RESISTANCE IN CHF 
possible cause 
kept no diet 
took no pills 
erratic GI absorption 
enlarged biotransformation 
impaired tubular secretion 
proximal tubular reabsorp­
tion increased 
distal tubular reabsorption 
increased 
nephrosis 
interaction 
low output state 
complicating illnesses 
simple detection aid 
ask, measure urinary Na 
ask 
-
-
exclude uraemia, probenecid? 
volume contraction signs? 
Na/K ratio > 1 
Na/K ratio < 1 
albustix 
NSAID? 
low RR, pulse +, kidney 
function + 
re-examine carefully 
possible solution 
instruct again or arrange 
low-salt diet service 
instruct again or arrange 
memory aid or supervision 
try intravenous route 
increase dose 
dialysis? stop competing drug 
consider mannitol, acetazola-
mide; metolazone? 
add thiazide/resp add loop 
diuretic 
add spironolactone 
increase dose; add metola­
zone? 
stop; if needed replace by 
simple analgesic (or sulin-
dac?) 
vasodilators; Captopril (90) 
appropriate treatment if 
possible 
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CHAPTER IV 
METHODS 
4.1 HPLC 
HPLC is the abbreviation of the name of an analytical method 
called m full: high-performance liquid chromatography; it is 
also described as high-pressure liquid chromatography, high­
speed liquid chromatography (HSLC) and by cynics as high-price 
liquid chromatography. HPLC possesses many of the attributes 
required of an ideal analytical system for clinical and pharma­
cokinetic studies. Analyses are frequently undertaken on biolo­
gical samples which may contain low levels of drugs and meta­
bolites contaminated with various possibly interfering substan­
ces. The method combines accuracy, precision, selectivity and 
sensitivity with speed of operation. In general, no denvati-
zation and only minimal extraction procedures are necessary. 
The basic HPLC system consists of a mobile phase reservoir, a 
high-pressure pump, an i^ection valve, a column, a detector 
and a recorder (1). 
Before a biological sample can be injected onto the column 
a few preparations arc necessary: 
- In the case of a highly protein-bound drug (as most diure­
tics are), it has to be liberated from its protein binding. 
Гог acidic drugs this dissociation is generally achieved by 
acid precipitation of protein. In the case of acid-labile 
drugs, other deproteimzmg methods or special precautions 
are necessary (as discussed for F in chapter VI). 
- Although in some instances direct infection of serum or urine 
may be used for assaying the drug, an isolation step is 
usually necessary to remove as much of the contaminants as 
possible, so that the column life is prolonged and detection 
made easier. In the case of F, most endogenous fluorescing 
substances are removed in this manner. Extraction with a 
suitable organic solvent is the method "-Ostly used. 
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- In the case of non-volatile drugs (like diuretics) the orga-
nic solvent is evaporated to dryness. The residue containing 
the drug and metabolites is redissolved in a small volume 
of the 'mobile phase'. 
- The selection of the mobile phase is perhaps the most impor-
tant single factor in achieving HPLC separations. The selec-
tivity of the system is usually ensured with the aid of only 
a few standard columns, but a variety of solvents and solvent 
mixtures. General aspects of mobile phase selection have 
been reviewed in literature (2,3). 
The sample is injected onto the column via an injection valve. 
Traditionally silica was the more polar stationary phase in 
this column and the mobile phase was relatively non-polar. 
Later on, "reversed-phase" columns have been developed: in 
these columns the surface silanol groups in the stationary 
phase (silica) have been modified by reaction (usually with a 
chlorosilane) to yield a non-polar surface coat, whereas the 
solvents (mobile phase) used through the column are highly 
polar. We used a 'reversed-phase' column in our experiments, 
packed with microparticulate, totally porous silica with a mean 
particle size of 5 y and surface areas of several hundreds of 
square metres per gramme. 
The choice of a detection method (UV detector, fluorescence 
detector or other detection methods) depends on the charac-
teristics of the molecules under study. These data are known 
or should be studied beforehand. 
The chemical properties of TA and its alcoholic metabolite 
made UV detection (at different wave-lengths for either of the 
two) most suitable. The native fluorescence of F at acidic pH 
let us choose a fluorescence detector in that determination 
method. 
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4.2 Protein binding of drugs 
Most drugs are carried from their sites of absorption to their 
sites of action and elimination by the circulating blood (4). 
Some drugs are simply dissolved in serum water, but most drugs 
are partly associated with blood constituents such as albumin 
globulins, lipoproteins and erythrocytes. For the majority of 
drugs, binding to serum albumin is quantitatively by far the 
most important. Albumin binding influences the fate of drugs 
in the body: only the unbound or free drug diffuses through 
capillary walls and reaches the site of action. 
Binding to serum albumin therefore may reduce the maximum 
intensity of drug action; the magnitude of the decrease depends 
on the fraction of the administered dose that is bound to al-
bumin. Since drug binding to albumin is usually readily re-
versible, the albumin-drug complex serves as a circulating drug 
reservoir. Changes in the free fraction of a drug in the serum 
can have important clinical consequences. The albumin-drug 
interaction depends on the concentrations of drug and albumin, 
and may be influenced by other drugs or endogenous substances 
present. For most drugs there are only one or two primary bind-
ing sites on the albumin molecule; secondary, less specific 
binding sites are often present. The binding can involve elec-
trostatic forces, hydrogen bonds, dioole-induced dioole bindino 
(Van der Waal's attraction) and hydrophobic interaction. 
The binding of drugs to serum protein has been studied by in-
vitro equilibrium dialysis, ultrafiltration or ultracentrifu-
gation. Nearly all studies on protein binding have been done 
with plasma (or albumin) in buffer solutions. The results of 
these experiments critically depend on the buffer system used 
(type,pH, ionic strength), on the albumin used (purified or 
crude, of human or animal origin), and on the temperature of 
incubation. Finally the age of the human albumin donor may be 
an independent factor, for a decrease in protein binding in 
old age has been described (5). In equilibrium dialysis two 
compartments (chambers) are separated by a semi-permeable 
membrane. Into one chamber a solution of albumin in "physio-
logical" buffer is pipetted, into the other a solution of the 
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drug under study dissolved in the same buffer. At equilibrium 
the total drug concentration is measured in the first chamber, 
free drug concentration in the other. These experiments are 
done with a wide concentration range of the drug and a more 
limited concentration range of protein (especially albumin). 
The reversible reaction between drug (D) and protein (P) lead­
ing to a drug-protein complex (DP) can be expressed as (6) 
D + Ρ І DP ( 1 ) 
As soon as equilibrium has been established this may be des­
cribed by an association constant (Ka) or its reciprocal, the 
dissociation constant (K^ = /K
a
) 
К - Ι/κ - [ρΙ ϊρ1 (2) 
Kd - / K a - [DP] u ' 
in which [D] = free drug concentration 
[P] = " protein " 
[DP] = concentration of drug-protein complex 
K
a
 is expressed in litres per mole (M ) , K^ in ituples per 
litre (M). A strongly bound drug has a large K
a
 and a small 
Κς[. The degree of binding at concentrations other than those 
measured can only be calculated exactly if the concentration 
of protein and the dissociation constant(s) of the drug-
protein complex are known. The total concentration of protein 
[Ptjequals [P] + [DP] of course, so equation (2) can be rewrit­
ten as 
[D] ( [Pt] - [DP] ) 
K d = (3) 
[DP] 
which may be rearranged to the form 
[DP]
 =
 JDJ (4) 
[Ptl " Kd + [D] 
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for the ratio [DP] / [Ptl the symbol r is frequently used; 
[DÍ-] may be regarded operationally as the concentration of bound 
drug. 
If there are a number (n) of identical separate binding sites 
on each protein (albumin) molecule, there are a series of 
equations of type (4) which may be summed: 
r - r-,
 + Г2 + .... rn - j^-T-fr] ( 5 ) 
The values of [D]and r can be measured experimentally. 
The classical procedure for analysis of data on protein binding 
is the Scatchard plot (7) in which r / [ D ] is plotted against r 
(= moles of bound drug per mole of protein*. 
A modification of the classical Scatchard plot is to plot 
[DP]/ [D] against f^ p] (which means that the variables on both 
axes are multiplied by [Pt] . 
The experimental data in the case of one group of binding sites 
with the same K¿ should fit a straight line, for equation (5) 
can be rewritten as 
r _J_
 + n_ (6) 
M Kd Kd 
If depiction of the experimental data results in a curvilinear 
Scatchard plot, this indicates that there is more than one 
group of binding sites with different dissociation constants. 
Instead of equation (5) the following equation applies: 
n1 1°] "2 [D] 
rtotal = Kdl + [Dj + K d 2 + |DJ + ···· (7) 
Determination of the values of nj, П2 etc and K^·,, K^» etc, 
involves repeated substitution of estimated values on a trial 
and error base until the curve is found which best fits the 
experimentally found curve. This procedure is greatly facili­
tated by computer programmes for non-linear regression. We 
used the FARMFIT programme (which is in use at the Computer 
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Centre of the University of Nijmegen). This programme performs 
non-linear regression of experimental data to explicitly for­
mulated model equations, which in the case of protein binding 
experiments consist of (equivalents of) the above equations. 
In general, several models have to be tested with regard to 
their suitability for fitting the experimental data. In the 
case of our protein-binding experiments a comparison was made 
between three different models, viz: the model with one group 
of binding sites (equation 6), the model with two groups of 
binding sites (equation 7 with n·] and П2) , and a model with 
one group of specific binding sites combined with a certain 
amount of non-specific binding. Discrimination between the 
various models is achieved by comparison of chi-square values. 
Most diuretics act after renal secretion and on the luminal 
surface of the renal tubule, and plasma protein binding is 
therefore only of minor relevance to their action: plasma 
protein binding prevents glomerular filtration of drugs but 
hardly influences tubular secretion, which is much more im­
portant in the case of diuretics. The response to diuretics 
may be changed considerably, however, if large amounts of 
protein are present in the glomerular filtrate, as is the case 
in the nephrotic syndrome. 
We used equilibruim dialysis to study the protein binding of F 
under conditions supposed to exist at the site of action of F 
(see chapter II). The results of these studies are reported 
in chapter VIII. 
4.3 Pharmacokinetics 
The intensity of the therapeutic and toxic effects of most 
pharmacological agents depends on their concentration at the 
sites of action. The time course of this concentration is de­
termined by the drug dosage schedule and by the fate of the 
drug in the body. Pharmacokinetics is the quantitative study 
of the processes of drug absorption, distribution and elimina­
tion. This section is not intended to explain the various 
types of pharmacokinetic models. For this aspect the reader 
is referred to textbooks and review articles (8-11). 
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Only some basic concepts, necessary for the understanding of 
chapter V and VII, will be discussed. 
Since it is obvious that any pharmacokinetic model should 
incorporate the fact that a drug is distributed throughout the 
body to a certain extent and that it is eliminated from the 
organism at a certain rate by the clearing organs (especially 
liver and kidney), the basic pharmacokinetic parameters are 
the apparent volume of distribution (V^) and the clearance 
(CI). As a rule these parameters are defined on the basis of 
plasma concentrations, so that V^ in principle is nothing else 
than the ratio of total amount of the drug in the body to the 
plasma concentration, and Cl represents the total rate of eli-
mination of the drug divided by its plasma concentration. 
The usual approach of pharmacokinetics involves the well-known 
compartment models. The basic assumption of these models is 
that the body can be divided into a central compartment with a 
relatively small apparent volume and one or more peripheral 
compartments, usually with larger apparent volumes. These com-
partments do not necessarily correspond to certain anatomical 
entities; they are theoretical spaces to account for the ex-
perimental observation that drugs are distributed in various 
body fluids and tissues at different rates. 
The central compartment comprises at least the blood plasma 
and usually also the highly perfused organs (including the 
major clearing organs), so that in a compartment model the 
drug enters and leaves the body via the central compartment. 
First-order kinetics describe the entry and exit of drugs into 
and from the compartments in the system. This assumption means 
that a drug is removed from a compartment at a rate proportional 
to the drug concentration in the compartment: the higher the 
drug concentration, the more drug leaves the compartment; the 
reverse is also true. 
Not all processes of drug transfer are first-order processes; 
elimination rate constants for instance can decrease as doses 
or plasma concentrations increase, resulting in dose-dependent 
elimination kinetics. This type of kinetics is caused nostlv 
by saturation of transfer or metabolic processes and is often 
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referred to as Michaelis-Menten kinetics (because enzymes are 
frequently involved and enzyme kinetics show these characteris-
tics) . On the other hand, elimination rate constants sometimes 
increase with increasing plasma concentrations. The usual cause 
of this is saturation of protein binding sites, resulting in 
relatively enlarged free plasma concentrations, which implies 
less hampered transfer processes. Only seldom is more than one 
peripheral compartment necessary for pharmacokinetic modelling. 
In our experiments, too, the two-compartment open model ade-
quately describes the time course of drug levels in plasma. 
The simplest method of drug administration for pharmacokinetic 
analysis is rapid intravenous injection (directly into the 
central compartment). Plasma drug levels are measured at frequent 
intervals thereafter. In the two-compartment model after rapid 
i.v. injection, a plot of the logarithm of these concentrations 
versus time yields a curve with two distinct linear components 
a phase with a rapid fall in concentration, called alphaphase 
or "distribution" phase, and a phase with a relatively slow 
fall in concentration, called betaphase or "elimination" phase. 
Mathematical analysis of the slopes and intercepts of the curve 
yields the pharmacokinetic parameters discussed below. Most 
drugs, however, are administered orally. Apart from the fact 
that in such a case a two-compartment system is often reduced 
to a one-compartment model (probably because the distribution 
phase is concealed by the absorption phase), three additional 
parameters have to be taken into account. Firstly, the rate 
constant of absorption (ka), which is a measure for the rate 
of absorption under the assumption of a first-order mechanism 
of the absorption process. Secondly, the lag-time, which can 
be regarded as the interval after oral administration during 
which no absorption takes place at all or only at much lower 
rate than that found later in the absorption phase. The lag-
time is an operational parameter needed to adapt actual measure-
ments to the model, but it may be related to factors such as the 
rate of disintegration of tablets or the presence of food in the 
gastrointestinal tract. Thirdly one should recognize the bio-
availability (F), i.e. the fraction of the dose administered 
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that reaches the general circulation intact. After oral admini-
stration there is some uncertainty in this respect: the drug 
may be incompletely absorbed and leave the body via the faeces, 
or it may be metabolized (and thus "eliminated") during the 
absorption process, either in the gut wall or in the liver du-
ring its first passage via the portal vein (first-pass effect). 
Regardless of the pharmacokinetic model used, it is possible 
to define relevant characteristics of the disposition of a drug 
with the aid of several often used parameters: 
1. Half-life. Any first-order process i?ay be described by a 
half-life. Especially the terminal half-life of elimination 
is a well-known parameter, also m clinical practice. This 
terminal half-life is based on the last logarithmic phase of 
drug disposition and represents the interval during which the 
concentration is reduced to half the value at the beginning 
of the interval. 
2. AUG (area under the curve). This is the total area (from 
zero to infinity) under the plasma concentration- versus-
time curve, which is obviously dependent on dose, bioavai-
lability, apparent volume of distribution and clearance. The 
AUG can be calculated easily by marking the plasma levels found 
at various times on linear (non-logarithmc) paper and con-
necting the consecutive datapoints by straight lines; in 
this way trapezia are formed and their surface areas can 
be calculated and added (trapezoidal rule). The main rele-
vance of the AUG is that it is related very simply to clearance 
(see below) and that in a fixed pharmacokinetic model it 
is directly proportional to bioavailability. 
3. Apparent volume of distribution (V^). In a one-compartment 
model V^ equals the volume of the central compartment and 
can easily be found as the dose divided by the (extrapolated) 
plasma concentration at zero time after i.v. injection. 
In multi-compartment models, several definitions of V^ are 
used. The most common ones are the volume of distribution 
at steady state (VJ ) and the volume of distribution during 
the ß-phase (Vdg, also called V d f a r e a ) . 
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vdss ^s ^n Principl6 only operational when there is no net 
transfer of drug into and from the compartments. Such a 
situation exists during continuous infusion, when a steady 
state has been reached. In that case it can be formulated as: 
k12 Vdss - V, <1 • ^ ) 
in which V- is the volume of the central compartment, and 
K-J2 e n K2i a r e th e r a t e constants of drug transfer between 
the central and peripheral compartments. 
For clinical practice, V¿jg often is more meaningful, also 
because it can be calculated more easily. The relevant 
equation is: 
D.tK 
Vdß ( Vd,area' 6.AUC 0.693.AUC 
(tè = 0 · 6 9 3 = the half-life of the "elimination" phase) 
Since distribution volumes are based on the drug concen-
tration in plasma, the apparent V·, may be very large (when 
a large fraction of the total amount of drug in the body 
resides outside the plasma). 
4. Clearance. The total body clearance is an index of drug 
elimination from the central compartment and could be ima-
gined as the volume which is totally "cleared" from the 
drug per unit of time. As long as linear kinetics prevail 
the following expression applies, regardless of the speci-
fic pharmacokinetic model applied: 
« = л§с 
Obviously this equation can also be written as: 
0.693 V,-
Cl = Ul 
і6 
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Clearance is by definition a purely additive parameter. One 
of the contributions, e.g. that from the renal pathway, can 
be measured independently. The renal clearance of a drug can 
be calculated by dividing the rate of urinary excretion of 
the drug by the plasma concentration. Alternatively, one can 
multiply total drug clearance by the fraction of the admini-
stered dose that appears unchanged in urine. 
For detailed analysis of our plasma curves we used Farmfit, a 
computer programme for non-linear regression analysis in use 
at the computer centre of the University of Nijmegen. This 
programme selects the best fit for the experimental data. On 
the basis of that fit and under the assumption of the compart-
ment model it calculates the relevant pharmacokinetic para-
meters as described above. 
4.4 DOSE-RESPONSE studies of diuretics 
It is a major goal of clinical pharmacology to understand the 
dose-effect relationship in therapeutics. Drug effects are des-
cribed by pharmaccdynairics (the study of how chemicals produce 
biological effects). 
In this section, background information is given that could be 
useful with regard to the protocols we used in the studies re-
ported in chapter V and chapter VII. We therefore confine our-
selves to assessment of the dose-response relationship of diu-
retic drugs (12), general information can be found elsewhere 
(13,14,15,16). The most direct approach to study the link be-
tween concentration and effect would be simultaneous measure-
ment of effect and concentration at the effect site. This is 
rarely possible in vivo, however. Application of pharmaco-
dynamics to the study of drug action in vivo therefore requi-
res pharmacokinetics to predict the dose-concentration rela-
tioship (17) on which the study of the concentration-effect 
relationship can be based. 
We studied TA and F, two diuretics acting at the luminal site 
of the renal tubule. Both are secreted into the urine in the 
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proximal tubule; TA has its site of natriuretic action in the 
distal tubule, F in the TALH. Measurements of drug concentra-
tions at the effect site are therefore impossible in man. So 
far as we know, both drugs are hardly reabsorbed after causing 
their effect, and urinary concentrations of these diuretics 
could therefore provide a useful stand-in for the 'do^e' side 
of the dose-response relationship. As illustrated in figure 
4.1, there must be a complicating factor: a few hours after F 
injection the urinary F concentrations rise, whereas the effect 
declines. This is probably a result of concentration of the 
tubular fluid in the collecting duct. Concentrating mechanisms 
are initially impaired as a result of the action of the loop 
diuretic (section 2.1) but later on (by the same mechanisms) 
the body tries to compensate for the induced losses of fluid 
and electrolytes. Nearly all studies of diuretic effects there-
fore do not use urinary or blood concentrations but the uri-
nary excretion rate of the drug (the amount excreted in a 
certain period of time) as an approximation of the concentration 
at the site of action (18-23). We used the same approach. 
Which parameter to choose as "response" is an even more deli-
cate problem. Simple clinical parameters are weight loss pro-
voked, urine volume produced in 24 hours or total amount of 
sodium excreted. These parameters, however, allow no complete 
study of a dose-response relationship in a single experiment 
in one individual. Somewhat more sophisticated methods are 
necessary, e.g. the use of the excretion rate of volume, sodium 
or chloride measured by analysing as many samples of urine as 
possible (24). These parameters, however, do not take the 
renal function of the individuals into account and are there-
fore only useful in the study of populations that are homo-
geneous as to renal function. The glomerular filtration rate, 
determining the salt load of the tubular system, is indeed 
the first determinant of sodium excretion. It seemed therefore 
more suitable for studies such as ours to express the dose-
response relationship taking into consideration the amount of 
substances filtrated at the glomeruli. This correction applies 
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both to interindividual differences in GFR (as was the case 
in the F studies) and to a considerable intraindividual de-
crease in filtrated load (as was the case in the TA study, 
where plasma uric acid level was approximately halved as an 
effect of TA). To construct dose-response curves we therefore 
used as the "response" the calculated fractional clearance, 
i.e. the fraction excreted; calculated by dividing the amount 
recovered in urine by the amount thought to have been present 
in the glomerular filtrate. The amount filtrated is determined 
by the free plasma level of the substance and the GFR; we 
estimated the GFR by measuring endogenous creatinine clearance, 
an indirect and not totally exact method, but the one most widely 
used and easiest to handle (25,26). In the TA study we used 
the fractional clearance of urate. In the F studies we chose 
the fractional clearance (f) of chloride after calculating 
other parameters as well (fig 4.1). This choice was based on 
the following considerations: 
- chloride handling is probably least influenced by post-TALH 
transport processes: in patients chronically treated with 
diuretics, both aldosterone (influencing sodium transport) 
and ADH levels (concerning water transport) are generally 
increased. 
- at the time we started our studies it was generally thought 
that furosemide acted by inhibiting active chloride trans-
port. 
- we could not use the combined sodium and potassium excretion 
(as same others have done in describing TALH effects), because 
we had to use concentrated KOH for the preservation of some 
samples (chapter VI). 
Fig 4.1 Example of the results of a combined pharmacokinetic-
pharmacodynamic study of F in an aged patient (patient 
2 of chapter Vllb). The upper left half of the figure 
depicts three different ways to set out the pharmaco-
kinetics. The right half of the figure depicts four 
different ways to set out the response (the results in 
two blank specimens are also shown). The lower left 
figure is an example of the ultimate form of the dose-
response curves used (cf fig 1 of chapter Vllb and fig 4 
of chapter VIII). The points marked with an asterisk are 
data found in the first urine sample after F infection. 
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A similar approach has been used by other investigators (27-
29). In all our studies the results from the first urine sample 
after injection did not fit in the 'dose-resnonse' curve based 
on the other samples. These data-points were always located as 
in the curves shown in figure 4.1, indicated by the asterisk 
symbol. A discussion of the factors causing this phenomenon is 
beyond the scope of this review. 
The clinician is of course most interested in the magnitude of 
the effect attained with a certain dose of a diuretic. We there-
fore searched for patient parameters useful in explaining the 
differences in diuretic effects observed, hoping that with one 
of these parameters a better dose tailoring could be achieved 
in advance. In paediatrics, dose tailoring is a common proce-
dure usually involving body weight. 
In the case of drugs acting on the adult or aged kidney, how-
ever, parameters of kidney function are probably most appro-
priate . 
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Summary. A simple and reliable H PLC method for 
the determination of tienilic acid ((TA) Sclacryn®, 
Selcryn®, Diflurex®, Ticrynafen®) and its alcoholic 
metabolite in plasma and unne has been developed 
In 8 healthy adult volunteers the plasma and unnary 
levels of tienilic acid and its alcoholic metabolite, 
and plasma and unnary levels of sodium, creatinine 
and une acid were measured after oral administra­
tion of tienilic acid 250 mg The pharmacokinetic 
parameters found differed only slightly from those 
reported in the literature, as there was faster absorp­
tion and a shorter half-life TA is probably excreted 
by a saturable renal tubular transport mechanism 
The pharmacodynamic effects of tienilic acid devel­
oped quickly, the uncosunc effect being very impres­
sive and the natriuretic effect moderate These ef­
fects disappeared in about 8 h An inverse relation­
ship was found between the starting plasma une acid 
level in an individual and the maximal une acid 
clearance - the higher the plasma uric acid level, the 
lower was the maximum effe« Plasma tienilic acid 
level and natnuretic effect were correlative within in­
dividuals and intra-individually (p < 0 05) Unnary 
tienilic acid level and natnuretic effect were correlat­
ed, too (p < 0 05 to ρ < 0 001), but only intraindivid-
ually No correlation between drug level and unco­
sunc effect was found 
Key words: tienilic acid, uncosuna, pharmacokinet­
ics, pharmacodynamics, une acid, diuretic, plasma 
level assay 
When this study was begun tienilic acid (TA, [2,3-
dichloro-4-(2-thien)lcarbonyl)-phenoxy] acetic acid) 
was a promising new antihypertensive drug, combin­
ing a diuretic with a uncosunc effect The hypoten­
sive effect of TA had been fully investigated [1, 2] in 
man, but much less was known about the diuretic 
and uncosunc effects in healthy volunteers, or in pa­
tients with oedema or raised plasma une acid levels 
We were especially interested m the question wheth­
er the charactenstics of TA would be the same in 
oedematous, hypertensive or hyperuncaemic pa­
tients as in healthy volunteers 
We developed an H PLC method for determina­
tion of TA and its main metabolite OH-TA (in which 
the carbonyl function is reduced) m plasma and 
unne, and subsequently measured drug levels and ef­
fects in healthy volunteers Shortly thereafter the 
work had to be discontinued because TA was with­
drawn from the market in most European countnes 
and in the USA [3] because of a suspicion that it 
might cause liver damage It was decided after all to 
process and publish the preliminary results, because 
TA was still being used in France and Switzerland, 
and because discussion about its reintroduction for 
more restricted indications continued [4, 5, 6] 
Materials and Methods 
TA and OH-TA were obtained from Smith Kline 
and French (Philadelphia, USA) Ethacrynic acid 
was obtained from Merck Sharp & Dohme (Rahway, 
New Jersey, USA) All other reagents were of analyt­
ical reagent grade and were obtained from E Merck 
(Darmstadt, FRG) 
Drug Administration 
Details of the healthy volunteers (22-31 years, 
6 males, 2 females) in the study are listed in Table 1 
After an overnight fast, each ingested one standard 
tablet containing TA 250 mg (Selcryn®), together 
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Table 1. Details of the subjects 
of 
volun­
teers 
AK 
JvV 
RT 
L L 
HvB 
TV 
A M 
FH 
weight 
[kg] 
72 
63 
79 
77 
107 
64 
60 
65 
pressure 
|mm Hg| 
120/ 80 
115/ 85 
125/ 85 
110/ 65 
145/ 85 
115/ 75 
150/100 
125/ 70 
une acid 
Immol/I) 
0.12 
0 29 
0 38 
0.28 
041 
0 37 
0 32 
0 34 
albumin 
I B / 1 ] 
48 
50 
48 
49 
47 
47 
44 
46 
creatinine 
clearance 
[ml/mm] 
110 
123 
130 
114 
150 
105 
82 
140 
with about 500 ml water to reduce any possible risk 
of formation of urate deposits in the kidney. Drug in­
take was at 9.00 a.m., and at 10.00 a.m. a standard 
breakfast was consumed. In order to imitate a nor­
mal patient situation, the volunteers were allowed to 
sit, walk and perform light physical activities. Smok­
ing was not allowed. From 1.00 p.m. the subjects 
were allowed to eat, drink and smoke freely, and to 
leave the laboratory. 
Sampling Procedure 
At regular times after drug administration (l = 0,1, 
2, 3, 4, 6, 8, 12 and 24 h) blood samples from a fore­
arm vein were collected in hepannized tubes. After 
centrifugation, plasma was separated and was stored 
in a deep-freezer ( — 200 С). Urine was voided, if pos­
sible spontaneously, at t = 0,0.5,1, 1.5, 2, 2.5,4,6, 8, 
12 and 24 h The samples of urine were in part frozen 
until assayed and in part processed, following the 
routine procedures of the Clinical Chemistry Labo­
ratory for clinicochemical determinations. 
Preparation of the Samples 
All plasma samples were analysed for TA and OH-
TA. In some of the samples, albumin, creatinine, 
urate [7], sodium and potassium were also deter­
mined. All urinary samples were analysed for TA, 
OH-TA, sodium, urate [7] and creatinine; if a deposit 
was formed (probably consisting of acidic compo­
nents such as urate), this was dissolved by increasing 
the pH ofthat sample by addition of 10% K.OH solu­
tion. 0.1ml of an internal standard solution (etha-
crynic acid 80 mg in methanol 100 ml) was pipetted 
into an extraction tube and evaporated to dryness, 
and plasma or urine 0.5 ml, 8.5 M acetic acid 0.5 ml 
and 5 ml of diethylether and n-hexane (volume ratio 
35 :65) were added. After mechanical shaking for 
30 min, the mixture was centrifuged for 15 min at 
1300 g. The organic phase was transferred to another 
tube in a heating block at 30 °C, and evaporated to 
dryness under a gentle stream of dry, filtered air. The 
residue was taken up in 1 ml of a 50:50 mixture of 
methanol and twice-distilled water and 10 μΙ of the 
solution was injected onto a column under the con­
ditions defined below. 
High Pressure Liquid Chromatography 
The apparatus used was a HP 1084 В (Hewlett-Pack­
ard) equipped with a variable wavelength detector, a 
microprocessor for controlling and evaluating the 
chromatographic run, and an automatic sampling 
device for easy, continuous use of the apparatus. The 
chromatographic column was stainless steel, length 
15 cm, internal diameter 0.46 cm, filled with reverse 
phase material Lichrosorb RP8 (5 urn particles, 
E.Merck, Darmstadt, FRG). The column was oper­
ated at 35 °C. The conditions were different for ТА 
and OH-TA: 
Procedure 1. ТА was chromatographed with a 
mobile phase of methanol and water (52.5 :47.5 vol­
ume ratio) containing 0.01 M citric acid, to which 
was added a solution of KOH (10%) until the pH of 
the mixture was 7.0. The flow of the mobile phase 
was kept constant at 1.4 ml/min. Detection by UV 
absorption was performed at 300 nm, which was op­
timal for TA and did not lead to any interference by 
OH-TA. 
Procedure 2 For OH-TA the methanol: water ra­
tio was changed to 45 :55, and the flow was also al­
tered, from 1.4 to 1.2 ml/min. UV detection was set 
at 245 nm because, unlike TA, OH-TA had its ab­
sorption peak at 245 nm. The apparatus was operat­
ed in the internal standard mode. Calibration was 
performed by a microprocessor (HP 79850 В LC 
terminal) with the aid of a standard solution contain­
ing ТА 50 μg/ml and ethacrynic acid 160 μg/ml. For 
OH-TA a similar calibration procedure was adopted. 
Comparison of amounts of drug and internal stand­
ard was based on determination of peak height ra­
tios. 
Pharmacokinetic Analysis 
The measured plasma concentration levels were sub­
jected to computerized kinetic analysis with the aid 
of the non-linear regression programme Farmfit'. 
The plasma curves showed exponential decay over 
sufficiently long time intervals, to afford simple reli­
able estimates of the pharmacodynamically relevant 
half-lives. 
A model-independent procedure, as indicated by 
van Rossum [8], was used to calculate the mean resi­
dence time (T), volume of distribution and total body 
clearance. 
1
 Farmfit, a non-linear regression programme for curve-fitting, is 
in use at (he С omputer Centre of the University of Nijmegen 
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stari start time(nnin) 
Fig. 1. A С hromdtogram оГ tiemlic ,icid in pUsma. a = tienilic 
acid (25 \ig/mi). b = internai standard cthacrynic acid (160 μg/ 
mi). * indicates 0 0016 absorbance unit В Chromatogram ui lien-
ilic acid and alcoholic metabolite in unne. a. b = endogenous UV 
absorbing substances, с - alcoholic metabolite of tienilic 
acid (50 μg/ml), d = tienilicacid ^50μg/ml). e = internal stand­
ard eihutrymc acid (160 μg/ml), * indicates 0 0016 absorbance 
unit (from start to 10 mm), and 0.0032 absorbance unit (Tor time -
10 mm on) respectively 
Finally, renal clearance was calculated by divid­
ing the average renal excretion rate over a certain in­
terval by the average plasma concentration over the 
same time period. Mean renal clearance over the 24-
hour period of experimentation was calculated by di­
viding the cumulative amount of drug excreted by 
the area under the plasma curve over the same peri­
od of time. 
Calculations 
The natriuretic effect of TA was calculated as sodi­
um excretion per unit time, and as fractional sodium 
clearance, i.e. the fraction of the sodium filtered in 
the glomeruli that was excreted in the urine. The 
glomerular filtration rate was estimated with the aid 
of the creatinine clearance, the equation used being: 
fractional clearance Na* = 
urinary sodium cone. . urinary creatinine cone. 
plasma sodium cone. ' plasma creatinine cone. 
The uricosuric effect of TA was calculated only as 
fractional urate clearance. The excretion of ТА and 
ОН-ТЛ was expressed as quantities per time unit, 
not as concentration. 
To test the correlation between drug level and ef­
fect, we preferred to use the first four hours after ad­
ministration of ТА (the time spent by the volunteers 
in the laboratory); presumed linear regression lines 
were calculated (method of least squares) if the as­
sumption of linearity was thought suitable after gra­
phic presentation of the data. Student's /-test for 
paired data was used. 
Results 
Analytical Procedure 
ТА produced optimal UV absorption at 300 nm. OH-
TA gave no absorbance at 300 nm but good absorb­
ance at 245 nm. At 245 nm the UV absorbance of ТА 
was half maximal. 
A chromatogram obtained after injection of a 
plasma sample containing ТА, and a urine sample 
containing ТА and OH-TA in combination with the 
internal standard, is shown in Fig. 1. Using Proce­
dure 1, the retention times of ТА and ethacrynic acid 
were 3.3 and 5.0 min, respectively. Using Proce­
dure 2, the retention times were prolonged to 7.1 and 
11.9 min, respectively, whereas the OH-TA eluted af­
ter 6.6 min, with fair separation from the TA peak. 
The average recoveries of ТА and OH-TA when 
taken through the extraction and chromatographic 
procedures were 95% and 91% respectively, as esti­
mated by comparing extracted samples with stand­
ard solutions. Plasma samples appeared to be stable 
when stored at -20 "C, and storage for 10 weeks 
caused no loss of tienilic acid. 
The precision of the H PLC procedure was deter­
mined by analysing ten times samples with known 
concentrations of TA. At a concentration of 50 μg/ 
ml, the standard deviation of the determination was 
1.49 (about 3.0%), and at a concentration of 4 μg/mI 
it was 0.25 (about 6%). For the range from 0 to at 
least 50 μg/ml. linear calibration graphs were ob­
tained when the peak height ratios of TA or OH-TA 
versus internal standard were plotted against the 
amount of drug or metabolite added (correlation co­
efficient > 0.999). The lower limit of detection of 
0.2 μg/ml for plasma and urine very satisfactorily 
covered the observed concentrations of TA. 
Pharmacokinetics 
The results of the pharmacokinetic analysis are sum­
marised in Table 2. After ingestion on an empty 
stomach, absorption appeared to be a relatively rap­
id process, peak levels being attained within 2 h. In 
one of the volunteers (FH), part of the absorption 
was delayed by about 4 h. As a result of this delay the 
plasma curve showed an oscillatory profile. 
fhc time of maximum plasma level did not vary 
much, but there were considerable differences in 
peak heights. The differences could not be related to 
body weight, creatinine clearance or serum albumin 
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Table 2 Pharmdcokmetics Cm^ and 1,^ are ihe observed level and Lime of ihe plasma peak t
 ω
 is the half life of absorption l
 x
\ repres 
ents the half life of elimination The area under the curve (AUG) is determined by trapezoid rule Τ is the mean residence time The total 
bod> clearance (CI) and the volume of distribution (V )^ are tabulated as values relative to bioavailability 
C„,„ lmg/I] 
U „ ( h ) 
lag lime [h] 
UW 
U d h ] 
AUC [mg h/1] 
T[h] 
CI/F[ml/min] 
CI/F[ml/min/kg] 
V j / F M 
V d /F[l/kg] 
A K 
14 3 
2 0 
05 
0 60 
1 56 
63 
3 0 
65 8 
091 
119 
017 
JV 
138 
20 
03 
0 45 
2 18 
61 
35 
68 0 
108 
144 
0 23 
RT 
187 
10 
05 
0 01 
1 51 
47 
22 
88 5 
1 12 
115 
015 
L L 
150 
20 
07 
0 45 
2 03 
59 
38 
70 5 
0 92 
16 0 
021 
HB 
14 2 
20 
02 
0 80 
160 
50 
28 
83 0 
0 78 
14 1 
013 
TV 
27 4 
2 0 
04 
130 
2 53 
109 
6 0 
38 3 
060 
Π 9 
0 22 
A M 
19 8 
20 
02 
0 35 
2 17 
105 
43 
39 7 
066 
103 
017 
FH' 
7 7/6 0 
2 0/6 0 
09 
035 
2 53 
47 
59 
88 2' 
136 
31 1 
048' 
α
 The profile of the plasma curve of subject FH showed two peaks Therefore, the estimates of Vj/Fand possibly ol Cl/Fin this case are 
erroneous 
Table 3 Renal Excretion Data 
C m J > TA[mg/l] 
C m j ,OH rA[mg/IJ 
Max excr rate TA |mg/h] 
Max excr rale OH TA [mg/h) 
Tolal amouru of TA excreted |mg/24 hi 
Total amount of ОН TA excreted [mg/24 h| 
Recovery TA + OH I A [% of dose] 
Renal clearance TA [ml/min) 
Subject 
AK 
84 0 
55 
17 
5 
65 
25 
36 
172 
JV 
58 5 
6 7 
17 
7 
37 
31 
27 
10 1 
R l 
59 0 
158 
14 
8 
39 
31 
28 
138 
LL 
1180 
69 
27 
7 
91 
30 
48 
35 6 
HB 
50 5 
6 0 
12 
6 
38 
28 
26 
125 
TV 
1060 
120 
22 
12 
73 
49 
49 
112 
A M 
64 0 
67 
10 
8 
65 
34 
40 
10 3 
FH 
915 
48 
11 
5 
55 
27 
31 
195 
Table 4 Renal clearance (Сік) of TA at vanous plasma levels 
Plasma concentration 
Range [mg/l] 
CIR [ml/mm ± SD] 
05 39 
40- 7 9 
8 0-12 9 
ПО 27 0 
2 1 3 ± 1 2 8 
2 0 7 ± 1 0 3 
15 1± 8 5 
1 2 7 ± 80 
17 
21 
24 
19 
π = number of observations 
level Two parameters describing elimination are list­
ed in Table 2 The first is the purely empirical appar­
ent plasma half-life, and the second is the overall 
mean residence time of the drug in the body The ap­
parent plasma half-life was short, from 1 5 to 2 5 h 
The mean residence time was equally short 2 2 to 
60 h Renal excretion data for TA and OH-TA are 
compiled in Table 3 Urinary TA concentrations 
were much higher than the corresponding plasma 
concentrations OH-TA also reached much higher 
concentrations in unne than in plasma, m which the 
level remained below 1 5 mg/l The total recovery of 
TA and OH-TA together ranged from 26% to 49% 
The ratio ΤΑ ΟΗ-ΊΑ differed in different volun­
teers The differences probably reflect the vanability 
of the reducing enzyme systems The renal clearance 
of ΤΑ, ι e the amount of TA excreted in unne di­
vided by the AUC, was quite small in all volunteers 
It is important here that TA is highly protein bound 
(> 99%, [9]), so that renal excretion of TA must be 
effected by tubular secretion If renal clearances 
were calculated by dividing the renal excretion rate 
over a certain period by the mean plasma concentra­
tion over that period, there appeared to be an inverse 
relation between renal clearance and plasma concen­
tration When the data for all volunteers are aver­
aged, it was found that renal clearance tended to de­
crease with increasing plasma concentration, sug­
gesting carrier-mediated transport (Table 4) 
Pharmacodynamics 
The results of two individual expenments are illus­
trated m Fig 2 The effect on sodium and une acid 
excretion started shortly after ingestion of TA and 
lasted for approximately 8 h The maximal effect on 
sodium excretion was seen after 1 to 4 h, the maxi­
mal effect on une acid excretion was seen earlier, aft­
er 1 to 2 h Sodium excretion was in the range expect­
ed for diuretics acting at the diluting site in the distal 
nephron, ι e an increase in fractional sodium clear­
ance from 0 1-0 4% to 1 6-4 0% 
The effect on uric acid excretion was impressive 
as there was an eight to fifteen-fold increase in uric 
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Fract urale clearance 
Fig. 2. Data of individuals Sodium excretion and ТА excretion 
are calculated over 30-min periods X axis 12 hour penod divided 
in six 2-hour parts 
Plasma uric acid 
[mmol] 
0.6 τ 
0 i 
О 2 
02 0¿ 0 6 08 
Clear une acid 
Clear creatinine 
Fig.3. Relation between plot of individual data on plasma uric ac-
id level ofthe volunteers (n = 8) before ingestion ofTA and maxi-
mal fractional urate clearance attained supposedly linear correla-
tion with r - 0 75, ρ < 0 05 
acid clearance - from 3-9% to 31-74% There was an 
inverse relationship between the starting plasma une 
acid level in a given individual and the maximal frac­
tional urate excretion attained in him (Fig.3). 
Correlation of Pharmacokinetics 
with Pharmacodynamics 
The correlation between the levels of ТА and OHTA 
in plasma and urine and the effects on sodium and 
uric acid excretion during the first four hours after 
administration are shown in Table 5. 
Sodium. In some individuals there was a significant 
relation between natriuresis and plasma ТА level. In 
all subjects there was a statistically significant rela­
tion between the excretion of sodium and the excre­
tion of ТА and OH-TA. There were marked interind­
ividual differences in the slope of the linear regres­
sion line calculated to obtain the correlation coeffi­
cient for the urinary data (listed in Table 5). The 
slope of the dose-response lines varied from 
39°-73° :X = O.SYtoX = 3.3Y(X: excretion of ТА 
in mg per 30 min; Y: excretion of sodium in mmol 
per 30 min). This emphasizes that calculations with 
pooled data were unjustifiable. 
An interindividual correlation between the high­
est plasma TA level attained and the maximal frac­
tional sodium clearance achieved (r = 0.74 ρ < 0.05) 
is shown in Fig. 4. 
Une Acid: As, Table 5 shows, the correlation between 
kinetics and dynamics for uric acid was less consist­
ent. The relation between urinary TA excretion and 
fractional uric acid clearance was highly variable; in 
five of the eight subjects studied, a closer relation of 
plasma TA levels to uric acid clearance was suggest­
ed. The results for uric acid did not indicate a corre­
lation between the maximal plasma TA level and the 
maximal fractional uric acid clearance. 
Clear Na*max 
Clear crealmine 
60 
20 30 40 
CmaxTA (mg/LI 
Hg.4. Relation between maximal fractional sodium clearance at­
tained and peak plasma TA level achieved in the eight subjects 
studied г = 0 74 ρ < 0.05 The wide range in peak ТА level is 
sinking 
Discussion 
The HPLC method of determination of ТА and OH­
TA proved to be reliable and easy to handle. Only 
one extraction step was necessary. For measurement 
of ТА alone, procedure 1 was accurate, but because 
there was interest in OH-TA as well, it was necessary 
to develop a second chromatographic and UV detec­
tion method. With the second procedure, however, 
measurement of TA was less sensitive and less accu­
rate, so samples were processed according to both 
procedures. 
Kinetics: The pharmacokinetics in only 3 of the 
8 subjects agreed well with a one compartment mod-
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Table 5. Correlation between pharmacokinetics and pharmacodynamics (r-value) between plasma TA levels and sodium excretion/frac­
tional urate clearance and between unnary TA excretion and sodium excretion/fractional urate clearance 
\ EITect 
\ ( Y ) 
Level \ 
(X) \ 
A K. 
J.v.V. 
R T . 
H v B 
L L . 
T V 
A . M . 
F.H. 
plasma 
unne 
plasma 
unne 
plasma 
unne 
plasma 
unne 
plasma 
unne 
plasma 
unne 
plasma 
unne 
plasma 
unne 
Na* - T A 
pomons 0-4 h 
0 97 ι 
0 97e 
0 67 
0 89b 
0.34 
0.94e 
0.84" 
0.80» 
0 79 
0.89ь 
0 65 
0 97e 
0 70 
0 92ь 
0 70 
0 96' 
Slope 
14 
13 
3 3 
28 
08 
13 
22 
18 
Na* « 
pomons 
0 95е 
0 88" 
0 87" 
0 97 ι 
0.%с 
0.83b 
0 97е 
0 94е 
ОН-ТА 
; 0-4 h 
hract urate — TA 
pomons 0-4 h 
0 95е 
0 77a 
0 90ь 
0 74a 
0 48 
011 
0 89ь 
0.49 
0 96е 
0 87ь 
0.37 
0.74a 
064 
064 
0 94е 
0І9Ь 
Fract. urale 
clearance — 
О Н Т А 
portions 0-4 h 
0 8 1 -
0 83ь 
- 0 1 2 
0.46 
0.88b 
048 
0.27 
0 82a 
The slope of the dose-response relation is expressed as m value (Y -
a
 =/>< 0.05. b - . / > < 0 0 1 , е = ^ < 0 0 0 1 
mX + C) 
el ; the curves in three others showed a moderate fit, 
and in 2 persons the plasma level - time curve was 
aberrant. One explanation of these findings is that 
the absorption of ТА deviated from mono-exponen-
tal kinetics. 
In fasting subjects faster absorption was ob­
served than that reported by Dubb et al. [9], but it 
was comparable to that reported by Wood et al. [10]. 
The apparent half-life found here was in agreement 
with the findings of Dubb et al. [9], and was shorter 
than the values reported by Wood et al. [10]. 
Like Dubb et al. [9] and Wood et al. [10], we had 
one volunteer with delayed absorption and an oscil­
lating plasma level versus time curve. This cannot be 
explained by the present data; the subject was not 
overtly different from the others. The withdrawal of 
TA from the market prohibited readministration to 
establish whether the individual peculiarity was con­
sistent. There was a marked difference in peak plas­
ma level. This difference could not be related to body 
weight, creatinine clearance or serum albumin level. 
Two factors may have contributed to the observed 
variability. First, the varying recovery rates of TA 
plus OH-TA in urine suggested a difference in bio­
availability; and second, the rates of absorption were 
different, especially in relation to the varying lag-
time, during which almost no absorption took place. 
Rough estimation indicated lag-times varying from 
0.15 to 0.95 h, which means that, in order to produce 
the relatively constant peak time which was found, 
the rate of absorption must have varied inversely 
with the lag-time. 
With the assumption of 50% bioavailability (an 
estimate compatible with the measured recovery of 
26-49% and data in the literature [9]), total body 
clearance was roughly 30 ml/min and distribution 
volume 3-5 1. These low values indicate that the drug 
was not extensively distributed, nor was it intensively 
cleared from the body. The combination of these two 
factors resulted in a short apparent half-life of elimi­
nation. When the renal excretion rate of TA was 
correlated with its plasma level the excretion rate 
was highest at low plasma TA levels and substantial­
ly lower at high plasma levels. This suggests that a 
readily saturable tubular transport of TA is the main 
renal excretory pathway, which would have made 
extensive kinetic studies of larger doses of TA very 
interesting. TA 500 mg was readministered to three 
of the volunteers; two showed capacity-limited elim­
ination kinetics, indeed indicative of a saturable re­
nal transport mechanism; and one volunteer (HvB, 
107 kg) eliminated the 500 mg according to first-
order kinetics. 
Dynamics: The rise in fractional sodium clearance 
from 0.2% to 3 4% after 2-4 h is consistent with a di­
uretic effect at the cortical diluting segment of the 
nephron, as elsewhere reported [11]. Natriuresis had 
returned to baseline in approximately 8 h. This infor­
mation and the short plasma half-life raise some 
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doubt about the claimed 24-hour hypotensive effect 
of a single daily dose of TA 250 mg. 
The rise in fractional uric acid clearance was 
spectacular, from 5% to 30-70% within 1-2 h of in-
gestion. The less marked maximal effect in the vol-
unteers with a borderline increase in plasma uric ac-
id levels was particularly sinking. The explanation 
could be that TA has a uricosuric effect mainly by in-
hibiting reabsorption of secreted uric acid [11]; if less 
uric acid is secreted in the tubules (as is probably the 
case in hyperuricaemic subjects), the maximal effect 
of TA cannot reach the same level. After administra-
tion on two occasions of TA to an aged hyperuricae-
mic (0.68 mmol/l) patient, on both occasions a maxi-
mal fractional urate clearance of only 27% was ob-
served. Lang et al. [12] observed the same phenomen-
on with probenecid and benzbromarone, and ad-
vanced the same explanation. 
The natriuretic and uricosuric effects of TA did 
not run in parallel, either in time or in the maximal 
changes produced; this is consistent with the find-
ings of Steele [11], and suggests a different site of ac-
tion. 
Connections Between Kinetics and Dynamics: The 
correlation between urinary data on TA and sodium 
supported the postulate that this diuretic, too, exert-
ed its natriuretic effect on the luminal side of the re-
nal tubule [11,13]. The excretion ofTA had to be ex-
pressed as quantity per unit time because the urinary 
concentrations measured were different from the ac-
tual concentrations in the cortical diluting segment 
of the nephron, probably due to the effect of ADH in 
the collecting tubule. 
The present data show no clear relation between 
the kinetics of TA and its uricosuric effect: no imme-
diate dependence on plasma or urinary TA level was 
consistently substantiated in the subjects. This con-
trasts with the findings of Steele [11] but he used 
pooled data to test the correlation. In the present 
series it was impossible either to refute or prove by 
statistical means the conclusion of Steele [11] that 
OH-TA is an inactive metabolite; OH-TA was not 
available for separate administration. 
To conclude, our principal question "Are there 
differences between healthy volunteers and patients 
as regards TA?", could not be answered because ex-
ternal events forced cessation of the experiments. 
However, two important indications of the answer 
emerged: 
1) Even in healthy volunteers, the slope of the dose-
response curve for natriuresis varied widely. 
2) The tendency to a diminished maximal uricosuric 
effect at a higher plasma uric acid level was clear. 
Hyperuricaemic patients, therefore, may not run 
a higher risk of developing renal uric acid depos-
its when TA administration is started. 
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SUMMARY 
A simple high performance liquid chromatographic method to measure furosemide in 
plasma and urine is described Furosemide fluoresces best, but is unstable, at acidic pH and is 
subject to photochemical degradation These factors were analysed and the results prompted 
changes in previously described methods 
All specimens were very carefully protected from light, extraction and acidification 
were done with acetic acid instead of hydrochloric acid With these precautions no 4 chloro 
5 sulphamoylanthranilic acid was found in biological specimens The main metabolite was 
furosemide glucuronide (20% of furosemide excretion) Sensitivity was 0 1 and 0 5 μκ/ιηΐ 
for plasma and urine, respectively The applicability of our method for furosemide studies 
is demonstrated 
INTRODUCTION 
Furosemide (F) is a potent short acting loop diuretic frequently used in 
oedematous states We searched for a reliable method to determine F and 
possible metabolites in both plasma and unne, for the purpose of pharmaco­
kinetic and pharmacodynamic studies with F in aged patients A reliable 
analytical method was deemed necessary, especially for unne samples, because 
the action of F seems to correlate best with urinary F levels [1—3] Sensitive 
methods make use of the fluorescence of F, which is optimal at low pH (4 5), 
but under these acidic conditions F is rapidly hydrolysed to 4-chloro-5-sulpha-
moylanthranihc acid (CSA), furfuryl alcohol and other degradation products 
[6, 7] This degradation may be even faster if sulphate ions are present [8] 
as in normal human unne Human unne is usually weakly acidic, and may be 
made more acidic by the action of F [9] 
Apart from this, mention has been made of photochemical degradation of F 
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[6] Several authors recommend exclusion of light [10—14], mostly without 
further explanation Apparently this is necessary during preparation or storage 
of unne samples only [15]. 
Some methods of F determination are described only for plasma [16—19], 
and no degradation problems are mentioned in these papers Nearly all methods 
of F determination so far described use hydrochlonc-acid extraction (see, for 
example, refs. 11, 12, 14—16, 20, 21] with the nsk of acid hydrolysis of F, 
and this probably led to the discussion m the literature about the nature of 
CSA (metabolite in vivo or degradation product, compare refs. 4, 11, 22, 23 
with refs. 13, 14, 24). Some authors report the existence of a glucuronide as a 
metabolite of F [13, 24] F had a рК^ of 3.8 (ρΚ
Λ
 7.5) and a protein-
binding capacity of 95—99%. After testing some of these factors, we developed 
a method for the high-performance liquid chromatographic (HPLC) determina­
tion of F which involves precipitation and acidification of the samples with 
acetic acid, exclusion of light, extraction with a diethyl ether—n-hexane 
mixture, and the use of desmethylnaproxen as internal standard. 
MATERIALS AND METHODS 
Reagents 
Furosemide and 4-chloro-5-sulphamoylanthranilic acid (CSA) were kindly 
supplied by Hoechst (Frankfurt, G.F R ), and desmethylnaproxen by Syntex 
(Palo Alto, CA, U S A ) ; β -glucuronidase was obtained from Sigma (St Louis, 
MO, U S.A.). Diethyl ether, n-hexane, acetic acid, methanol, sodium 
dihydrogen phosphate, disodium hydrogen phosphate, orthophosphonc acid 
and sodium hydrogen carbonate were all of analytical grade (E. Merck, Darm­
stadt, G F.R.), diethyl ether was distilled shortly before use. 
Biological fluids 
Human plasma which had been stored at —20° С was obtained from the local 
blood bank, human unne was collected from a male donor shortly before 
analysis From one male volunteer (31 years old, 70 kg) and one patient with 
congestive heart failure (68 years old, 60 kg) blood and unne were collected 
after oral administration of a 40-mg F tablet after an overnight fast. 
Sample preparation 
To find a good precipitation—acidification procedure the following solutions 
were prepared, before extraction with diethyl ethei^-n-hexane (65:35), m sub­
dued daylight in dark-brown test-tubes (in duplicate, see also Table I, left-hand 
column): 
(1) 5.2 jig of furosemide in 5 ml of diethyl ether—n-hexane mixture; 
(2) 5.2 ^g of furosemide in 5 ml of diethyl ethei—n-hexane mixture with 
20 μΐ of 1 5 M hydrochloric acid; 
(3) 5 1 Mg of desmethylnaproxen in 5 ml of diethyl ether—n-hexane mixture; 
(4) 5 1 Mg of desmethylnaproxen in 5 ml of diethyl ether—n-hexane mixture 
with 20 μΐ of 1 5 M hydrochloric acid, 
(5) 5.2 Mg of furosemide and 5 1 Mg of desmethylnaproxen in 5 ml of diethyl 
ether—n-hexane; 
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TABLE I 
SAMPLE COMPOSITION AND RECOVERY RATES OF FUROSEMIDE AND 
DESMETHYLNAPROXEN SOLUTIONS IN DIETHYL ElHER-n HEXANE USING 
ACETIC ACID OR HYDROCHLORIC ACID AS ACIDIFICATION AGENT 
For details of sample preparation see Materials and Methods section 
1 
2 
3 
4 
1A 
2A 
ЗА 
4A 
5 
6 
Sample 
Furoeei 
+ 
+ 
— 
— 
+ 
+ 
— 
— 
+ 
+ 
composition 
Hide Desmethyl-
naproxen 
— 
— 
+ 
+ 
— 
— 
+ 
+ 
+ 
+ 
HCl 
— 
+ 
— 
+ 
— 
— 
— 
— 
— 
— 
Acetic 
acid 
— 
— 
— 
— 
— 
+ 
— 
+ 
— 
+ 
Recovery (%) 
100 
6 5 , 5 2 
100 
8, 12 
100 
100 
100 
100 
100 
100 
(6) 5 2 Mg of furosemide and 5 1 Mg of desmethylnaproxen with 20 μΐ of 8.5 
M acetic acid 
The solutions were evaporated to dryness with a gentle stream of nitrogen at 
30° С The residue was dissolved in 1 ml of a methanol—0 01 M sodium 
bicarbonate mixture (3 2) The solutions were measured as described below 
The same tests were repeated, using 20 μΐ of 8 5 M acetic acid instead of 20 μί 
of 1 5 M hydrochloric acid (Table Ι, ΙΑ—4A) 
Stability tests 
The samples of F in unne obtained during a pharmacokinetic study were 
divided into three portions and processed immediately and after 20 and 45 
days of storage at —20oC in the dark (concentration range was 3—23 jug/ml for 
urine and 0 1—5 6 /ug/ml for plasma) Samples of F m plasma obtained during 
another pharmacokinetic study were measured after four days and four months 
of storage 
Solutions of F (130 /jg/lO ml) were prepared in phosphate buffer at pH 
3 5, 4 0, 4 5, 5 0, 5 5, 6 0, 6 5, 7 0, 7 5 and 8 3 in twilight These solutions 
were exposed to standard laboratory lighting at room temperature (fluorescent 
lights Philips TL 40 W/34 de Luxe at 1 5 metres) At time zero, and 0 75, 1, 
1 5, 2, 2 25, 3, 3 5, 4 and 5 25 h, 1-ml samples were mixed with 1 ml of 
methanol and measured directly by injection onto the column as described 
under Apparatus The same procedure was earned out with samples of CSA 
(250 μg per 10 ml) and with solutions of F in human urine 
Solutions of F (130 ug per 10 ml) and CSA were made in phosphate buffer 
at pH 3 0, 5 5, and 8 0 in twilight This time the solutions were protected from 
light, at time zero, and at 1, 2, 3 and 4 h, 1-ml samples of each solution were 
mixed with 1 ml of methanol and measured directly by injection onto the 
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column as desenbed under Apparatus No precautions were taken to prevent 
contact of the samples with air, and no efforts were made to expel oxygen from 
the solutions. 
Determination of F glucuronide 
Every aliquot of urine from a volunteer taking F and from a patient using F 
chronically was divided between two test-tubes: one for F determination, 
which was processed as described under Final procedure, and the other for 
determination of F and F glucuronide together 
The contents of the second test-tube were adjusted to pH 6 8 with KOH 
(20%) or H3PO4 (10%), the added volume of KOH or H3PO4 was negligible 
(maximum 40 μΐ to 12-ml tube). To an extraction tube containing an amount 
of internal standard (100 μΐ of a solution of 6 25 mg of desmethylnaproxen in 
100 ml of methanol, evaporated to dryness) were added 0 25 ml of this urine 
and 0.25 ml of 0 075 M phosphate buffer (pH 6.8) containing 500 units of 
^-glucuronidase The extraction tube was closed with a screw-cap The mixture 
was incubated for 21 h at 3TC in the dark After chilling to room temperature, 
0.5 ml of 8 5 M acetic acid and 5 ml of the extraction mixture (diethyl ethei^ 
n-hexane) were added, and the sample was processed further as described under 
Final procedure and measured as described under Apparatus 
Final procedure 
The expenments were earned out in subdued daylight In a dark extraction 
tube with polytetrafluoroethylene (PTFE) screw-cap, 100 μΐ of internal 
standard (6 25 mg of desmethylnaproxen per 100 ml of methanol) were 
pipetted and evaporated to dryness under a gentle stream of nitrogen at room 
temperature. Ahquots of 0 5 ml of plasma or unne (stored in the dark), 0.5 ml 
of 8.5 Λί acetic acid and 5 ml of diethyl ethei^-n-hexane (65 35) were 
successively pipetted into the extraction tube. The extraction tube was closed 
with the screw-cap and shaken mechanically for 30 mm, followed by 
centrifugaron at 1300 g for 15 mm The organic layer was pipetted into 
another dark-brown test-tube and evaporated to dryness with a nitrogen stream 
at 30° С The residue was dissolved in 0.6 ml of methanol (1 ml for urine) 
After addition of 0.4 ml of 0 01 M NaHCO, (1 ml for urine), 10 μΐ of this 
mixture were injected onto the column and measured under the conditions 
desenbed under Apparatus Before quantitative measurements were under­
taken, an internal standard method was calibrated with the aid of a Hewlett-
Packard 3353 Lab Auto System (with the option of measuring peak height 
instead of peak area), using a plasma calibration solution of 5 Mg/ml furosemide 
and 12.5 Mg/ml desmethylnaproxen. This was done to enable the computer to 
discriminate between the internili standard peak and the furosemide peak 
After calibration, a standard senes with the following concentrations was 
injected: 0 27, 0 53, 1.06, 2 12, 3.18, 4 24, 5.30 jug/ml of plasma A basic 
programme calculated the regression line of the standard curve with the peak 
height ratio of furosemide to internal standard. The concentrations of the 
samples were calculated according to the regression line. 
The same procedure was carried out for urine The calibration solution for 
urine was 50 μg/ml furosemide and 12.5 μg/ml desmethylnaproxen. The stan-
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dard senes had the following concentrations: 1.04, 2.60, 5.19, 10.38, 20.76, 
31.14, 51.3 μg|ml of urine. 
Apparatus 
A Hewlett-Packard HP1081B high-performance liquid Chromatograph 
equipped with a variable-volume injector was used. The stainless-steel column 
had a length of 15 cm and an internal diameter of 4.6 mm, and was packed 
with LiChrosorb RP-8, particle size 5 ¿im (Merck). The oven temperature was 
350C and the injection volume was 10 μ\. Furosemide and the internal standard 
desmethylnaproxen were measured with a fluorescence spectrometer Model 
3000 (Perkin-Elmer); the excitation wavelength was 275 nm (for urine 235 
nm), the emission wavelength was 410 nm (for urine 400 nm), and the 
excitation and emission slits were 10 nm. 
The mobile phase, consisting of methanol—0.02 M phosphate buffer, pH 3.0 
( l ' I ) , was delivered at a rate of 1.0 ml/min, the resulting pressure being 240 
bars. 
Pharmacokinetic pilot study 
A male volunteer (31 years old, 70 kg) took a standard 40-mg furosemide 
tablet (Lasix®) at 9.00 a.m. after an overnight fast. Blood samples were taken 
at time zero, and at 0.5, 1, 1.5, 2.25, 3, 5.5 and 6.5 h. A blank urine sample was 
voided at time zero and further samples at 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 
3, 5, 8 and 12 h, directly into dark-brown bottles. 
One male patient (68 years old, 60 kg), who during 10 days had been using 
furosemide for congestive heart failure, took his eleventh standard tablet of 40 
mg furosemide (Lasix®) at 9.00 a.m. after an overnight fast. Blood was sam­
pled at time zero, and at 0.5, 1, 1.5, 2, 2.5, 3 and 4 h. Urine samples were 
collected after spontaneous voiding, which was rather irregular. By mistake two 
specimens were not protected from light immediately. 
RESULTS 
Studies on the influence of acidification 
Using hydrochloric acid (15 ili) as acidification agent, we obtained a 
recovery of about 50% for F and 10% for the internal standard because of de­
composition of F and desmethylnaproxen. Using acetic acid (8.5 M) as acidifi­
cation agent, no degradation of F or desmethylnaproxen was observed Details 
are given in the right-hand column of Table I and under sample preparation in 
Materials and Methods. 
Stability tests' storage of urine and plasma 
If the pharmacokinetic samples of urine were immediately protected from 
light and stored at — 20°C, we found a recovery of 97 ± 7% (mean ± S D.) after 
20 days and of 94 ± 7% after 45 days. This recovery was the same with 
biological samples of urine of pH 5—8 and various F concentrations of 3—23 
iig/ml. In the plasma samples measured after four months, we found a recovery 
of 102 ± 3% in the lower as well as in the higher concentration range. 
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Stability tests influence of light at uanous pH values 
If F was exposed to light (see Table II), fast hydrolysis took place which 
resulted in at least three compounds, highly dependent on the pH of the F 
solution. The degradation products had retention times of 1.93 min (F,), 
2.85 min (F2) and 5 43 min (F3) A degradation product of F with a retention 
time of 2.85 min (Fj) in the chromatographic system was much more 
fluorescent under the detection conditions than furosemide itself (Fig 1) No 
degradation product with a retention time identical to CSA (2.1 min) was 
found Decomposition of F appeared to obey first-order kinetics, and 
consequently a decomposition half-life of F could be calculated as shown in 
Table II. Apart from this we found further decomposition of pure CSA 
solutions, which we could not identify because the peak of the decomposition 
product of CSA (1 94 min) overlapped with the CSA peak (2 10 mm) (see Fig 
2). When instead of water we used human unne in view of the possible 
influence of sulphate ions, the results were not significantly altered (nor more 
pronounced either) When the samples of F in 0.01 M phosphate buffer of pH 
3 0—5 5 and 8.0 were protected from light at room temperature, there was 
100% recovery after 4 h, whereas after 24 h we found only negligible decom­
position peaks. 
TABLE II 
RECOVERY OF ' FUROSEMIDE 
EXPOSED TO LIGHT 
Time exposed 
to light 
(h) 
0 
0 75 
1 
1 5 
2 
2 25 
3 
3 5 
4 
5 25 
(ц decomp (h) 
pH 
3 5 
100 
75 
46 
26 
10 
7 
1 1 
4 0 
100 
81 
60 
39 
24 
18 
1 7 
(%) FROM 
4 5 
100 
89 
81 
59 
55 
51 
4 
5 0 
100 
97 
91 
67 
62 
ND* 
5 
SOLUTIONS ι 
5 5 
100 
95 
90 
81 
76 
10 
6 0 
100 
95 
90 
84 
78 
11 
OF DIFFERENT pH 
6 5 
100 
96 
92 
82 
78 
11 
7 0 
100 
99 
95 
84 
81 
13 
7 5 
100 
100 
98 
88 
84 
16 
WHEN 
8 3 
100 
94 
89 
84 
84 
16 
*ND - not determined 
Finoi procedure 
When we used blood bank plasma and human urine, the recovery of F in 
plasma was 85 ± 2% at concentration 5 Mg/ml and 89 ± 3% at concentration 
0 5 Mg/ml, in urine the recovery was 95 ± 2% at concentration 50 Mg/ml, 
97 ± 3% at concentration 25 jug/ml and 95 ± 2% at concentration 2 5 Mg/ml 
With plasma furosemide concentrations of 0.27—5.3 Mg/ml, there is a linear 
relationship between the peak height ratio of furosemide to internal standard 
(Y) and the plasma F concentration (X), as given by the equation Y = 0.114X 
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Fig 1 Effect of light on a furosemide solution consisting of 130 vg of F dissolved in 10 ml 
of 0 01 Λί phosphate buffer (pH 4 0), 1 ml samples were processed and measured Left 
chromatogram of sample protected from light Centre chromatogram of sample processed 
after 0 75 h under fluorescent lights degradation products F, and F, are visible Right 
chromatogram of sample processed after 5 25 h under fluorescent lights, degradation 
products F,, Fj and F, are present 
Fig 2 Effect of light on a CSA solution formed by dissolving 250 μι of CSA in 10 ml of 
0 01 Λί phosphate buffer (pH 4 5), 1 ml samples were processed and measured Left 
chromatogram of a sample protected from light Right chromatogram of a sample processed 
after 0 Ti h under fluorescent lights, the overlap of degradation peak CSA, and original CSA 
peak results in an apparent rise in CSA peak height 
+ 0 0013 (r = 0 9998, η = 7) With unne concentrations of 1 04—51 9 μξίτηί, 
there is a linear relationship between urinary F concentration (X) and peak 
height ratio ( Y), described by the equation Y = 0 020X — 0 0038 (r = 0 9999, 
η = 7) 
At a given plasma F concentration of 0 54 Mg/ml, the coefficient of variation 
is 2 67% (n = 10) 0 5401 ± 0 0144 (range 0 514-0 560) At a given plasma F 
concentration of 2 04 Mg/ml the coefficient of variation is 3 50% (n = 10) 
2 038 ± 0 0713 (range 1 98-2 18) At a given urinary F concentration of 3 61 
Mg/ml, the coefficient of variation is 2 35% (n = 9) 3 614 ± 0 085 (range 3 47— 
3 70) At a given urinary F concentration of 21 81 Mg/ml, the coefficient of 
variation is 1 60% (n = 10) 21 814 ± 0 3482 (range 21 36-22 26) Under the 
conditions described under Apparatus, the retention time of CSA was 2 1 mm, 
that of F was 4 2 mm and that of the internal standard desmethylnaproxen 
was 6 0 mm (Figs 3 and 4) In the case of accidental exposure to light during 
the procedure, peaks of degradation products appear The lower limit of detec­
tion in plasma with spiked samples using an internal standard of 2 5 jug of des­
methylnaproxen mstead of 12 5 Mg/ml is 0 1 μg/m\ (0 1 i 0 08, η = 10, range 
0 09—0 12) The lower limit of detection in urine is 0 5 ßg/ml (0 41 + 0 02, 
η = 10, range 0 45—0 52) This covers very satisfactorily the drug levels at 
which the diuretic effects of F occur 
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Fig 3 Left chromatogram of blank plasma with small peaks of endogenous fluorescent 
substances at 3 8 and 5 3 mm Right chromatogram of plasma containing 1 Mg/ml 
furosemide at 4 2 mm and 25 и gl ml desmethylnaproxen (internal standard, I S ) at 6 0 mm 
Fig 4 Chromatograms of (left) blank urine and of (right) urine containing 2 5 Mg/ml 
furosemide and 25 jig/ml desmethylnaproxen (internal standard, 1 S ) 
Pilot pharmacokinetic studies 
In the adult volunteer the peak plasma level was 1 8 /ig/ml at 1 h. The 
elimination half-life was determined as 1 06 h and the area under the curve 
(AUG) for plasma as 3.6 mg h per 1. The renal furosemide clearance was 70 ± 
20 ml/min. The recovery of F in urine was 14.54 mg after 12 h, recovery of F 
glucuronide in urine was 3.55 mg, total recovery in urine during 12 h was 18.1 
mg (45%). No trace of CSA or other metabolites was found. There was a good 
correlation (r = 0.84, ρ < 0.01) between urinary F excretion per mm and uri­
nary water excretion (as a global parameter of diuretic effect) during the first 
3 h; this correlation extended also over the period 0—8 h (ρ < 0.001, г = 0.88) 
(see Fig. 5). 
In the older patient, resorption was somewhat delayed: a peak plasma F 
level of 1.7 /ig/ml was attained at 1.5 h, elimination half-life was 0.8 h and 
AUG for plasma was 3.1 mg h per 1 (renal furosemide clearance was approxi­
mately 73 ± 27 ml/min, but only four specimens were available for this estima­
tion). The recovery of F in urine was 13.7 mg after 24 h, and recovery of F 
glucuronide in unne was 3.9 mg, m the two specimens exposed to light by the 
patient we found no CSA, but after pretreatment of the specimen with 0-gluc-
uromdase (in the dark) we found a major peak in the chromatogram with a 
retention time of 2.85 min (Fj, Fig. 1). No trace of this substance was found 
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Fig 5 Left plasma level versus tune curve after ingestion of a 40 mg furosemide tablet by a 
healthy volunteer Right urinary furosemide excretion (Mg F ехсг ) and urinary volume 
(UV) versus time 
m the properly handed specimens The patient was unable to void frequently 
enough to enable pharmacodynamic studies 
DISCUSSION 
Vanous problems with other methods of F determination are described in 
the Introduction Acidification of plasma samples is necessary to separate F 
from its protein bmding and to transfer it to an organic layer Acidification of 
unne samples is advisable to minimise the presence of endogenous fluorescing 
substances in the organic layer 
We did not use N-benzyl CSA [20] as internal standard because it has a 
longer retention time and is less stable under our experimental conditions than 
desmethylnaproxen We did not use dichloromethane or chloroform extraction 
because these chemicals extract too much endogenous fluorescing substance 
Our diethyl ether—π hexane (65 35) extraction mixture was unsuitable if used 
after HCl precipitation and acidification of the F samples, probably because the 
organic layer contained traces of water with hydrochloric acid, and furosemide 
is very unstable in HCl solution, as demonstrated (see Results and Table I) 
When acetic acid was used, no degradation of F could be observed The 
problem seems to have been encountered before, since Steiness et al [14] used 
a different acidification for unne (phosphate buffer) than for plasma (HCl) 
Unne samples containing furosemide could not be kept m the deep-
freezer for an indefinite time because this is likely to cause a slow decrease in 
recovery rate We brought to light the degradation problems in handling 
furosemide Especially acidic specimens of F should be kept in the dark from 
the time of taking the sample until injection onto the HPLC column, decom 
position was astonishingly fast, and degradation into vanous products occurred 
The degradation product F! of furosemide, with a retention time of 1 93 mm 
m our HPLC procedure, may well be identical to degradation product CSA, 
with a retention time of 1 94 in our system We were unable to identify CSAi 
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in relation to F, because chromatographic separation of CSA! from CSA was 
far from complete With proper handling of samples our method is hardly 
labonous. In sensitivity and reliability, our method does not differ from other 
published methods In plasma samples with concentrations of 0 1—1 0 /ig/ml, 
we now use an internal standard solution of 1 25 mg of desmethylnaproxen per 
100 ml of methanol (calibrating a standard curve with 0 1, 0 2, 0 5, 1 0 and 1 5 
μg/ml solutions of F) In unne, the concentration range related to the diuretic 
effect of F is far above our lower limit of detection, it is therefore unnecessary 
to reduce the amount of interal standard, although this would be possible m 
the same way The preliminary studies in man produced results similar to those 
mentioned in other reports in the literature Discussion about the existence of 
metabolites of F in man could hardly be touched in this preliminary study we 
did find a glucuromde in considerable amounts, we did not find CSA itself in 
the specimens from the adult volunteer, from the semi-chronic user of F too 
few good unne specimens could be obtained to permit detailed analysis The 
Fj glucuromde we found was probably an in vitro breakdown product of F 
glucuromde, and the F glucuromde excretion in this patient must therefore 
have been even more than the 3 9 mg mentioned Further studies are in 
progress 
ACKNOWLEDGEMENTS 
Valuable advice about the HPLC procedure was given by the late Huub 
Ketelaars The excellent secretanal assistance of Miss L W M Tempelman is 
gratefully acknowledged 
REFERENCES 
1 J Honari, A D Blair and R E Cutler, Clin Pharmacol Ther , 22 (1977) 396—401 
2 M Homeida С Roberts and R A Branch, Clin Pharmacol Ther , 22 (1977) 402—409 
3 В OdlindandB Beermann, Clin Pharmacol Ther 27(1980)784—790 
4 AW Forrey, В Kimpel, A D Blair and R E Cutler, Clin Chem , 20 (1974) 162—158 
б E T Lin, D E Smith, LZ Benet and В A Hoener, J Chromatogr 1 6 3 ( 1 9 7 9 ) 3 1 5 — 
321 
6 Ρ С Rowbotham, J В Stanford and J К Sugden, Pharm Acta Helv , 51 (1976) 304— 
307 
7 К A Kovar, G Ρ Wojtovicz and Η Auterhoff, Arch Pharm , 307 (1974) 657—662 
8 К A Shah, V D Gupta and К R Stewart, J Pharm Sci, 69 (1980) 594-596 
9 Μ Goldberg, in J Orloff and R W Berliner (Editors), Handbook of Physiology, Section 
8, Renal Physiology, American Physiological Society, Washington, DC, 1973, pp 1003— 
1031 
10 A D Blair, A W Forrey, Β Τ Meysen and R E Cutler, J Pharm Sci, 64 (1975) 1334— 
1339 
11 E Mikkelsen and F Andreasen Acta Pharmacol Toxicol, 41 (1977) 254—262 
12 В LindstrSm, J Chromatogr , 100 (1974) 189—191 
13 В Beermann, E Dalen, В LindshrSm and A Rosen, Eur J Clin Pharmacol, 9 (1976) 
6 7 - 6 1 
14 I Steiness, J Christiansen and E Steiness, J Chromatogr , 164 (1979) 241—246 
15 К Can, A Rane and J С FrSlich, J Chromatogr , 145 (1978)421-427 
16 F Andreasen and Ρ Jacobsen, Acta Pharmacol Toxicol , 35 (1974) 49—57 
17 В Lindström and M Molander, J Chromatogr , 101 (1974) 219—221 
18 R L Nation, G W Peng and W L Chiou, J Chromatogr , 162 (1979) 8 8 - 9 3 
79 
19 M. Schäfer, H E. Geisaler and £ Mutschier, J Chromatogr , 143 (1977) 636- 639 
20 S.E. Swezey, P.J. Me f Π η and T.F. Blaschke, J Chromatogr , 174 (1979) 469—473 
21 Ρ HaydúandA Haussler, Arzneim.-Forsch , 14 (1964) 709—710. 
22 Α Hausslerand Ρ. Haydú, Arzneim.-Forsch , 14 (1964)710-713 
23 G J Yakatan, D D Maness, J Scholier, W J Novick and J Τ Doluisio, J Pharm Sci , 
65 (1976) 1456-1460 
24 D E Smith, E T. Lin and L Ζ. Benet, Drug Metab Dispos., 8 (1980) 337—342. 
80 
CHAPTER VII 
a. CHANGES IN PHARMACOKINETICS AND IN 
EFFECT OF FUROSEMIDE IN THE ELDERLY 
ALM Kerremans, FWJ Gribnau 
Clin Exp Hypertension 1983, in press 
b. PHARMACOKINETICS AND PHARMACODYNAMICS 
OF FUROSEMIDE IN AGED PATIENTS 
ALM Kerremans, Y Tan, H van Baars, 
CAM van Ginneken, FWJ Gribnau 
Clin Pharmacol Ther 1983, in press 
81 

CHANGES IN PHARMACOKINETICS AND IN EFFECT OF 
FUROSEMIDE IN THE ELDERLY 
A.L.M. Kerrenians and F.W.J. Gribnau 
Division of Clinical Pharmacology and Pharmacokinetics 
Institute of Pharmacology 
University of Nijmegen 
6500 HB NIJMEGEN 
The Netherlands 
ABSTRACT 
In this paper the general changes in the pharmacokinetics of 
drugs in the elderly are summarized. The suggestion is proposed, 
that in the case of diuretics - which act after renal excretion -
the results of these changes are totally different: contrary to 
other drugs the standard dose of a diuretic must have less sali-
uretic effect instead of more effect. 
This thesis is supported by the results of experiments with furo-
semide in old patients: the kinetics are changed as expected, 
leading to higher plasma levels and increased Area Under the 
(plasma level versus time) Curve (AUC), but the effects are -
dependant on renal function - decreased. To a certain degree 
kinetics and dynamics of furosemide can be explained and predicted 
on the basis of simple patient parameters. If diuretics are used 
in old people to treat congestive heart failure, the normal adult 
dose has to be used, and occasionally a larger dose has to be 
given. 
INTRODUCTION 
Most drugs are studied in young, healthy, predominantly male 
volunteers in single-dose experiments. Most drugs are used by old, 
far from healthy, predominantly female patients on a chronic base. 
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Fig. 2. Suggested adaptation of the diagram for diuretics 
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Our knowledge about the effect of old age and chronic treatment 
on drug handling is therefore incomplete (9). 
What happens in old age with the handling of drugs? Fig. 1 
is an adapted version of the diagram which has been published by 
a WHO working party in Drugs (20): 
- the absorption of drugs is nearly always unchanged; 
- the volume of distribution can be slightly greater or smaller, 
partly caused by a decrease in plasma protein and plasma protein 
binding, partly caused by a change in body composition (less 
water, less muscles, more fat); 
- the metabolism of a number of drugs is lessened, many drugs are 
metabolized at a normal rate; 
- the renal excretion of drugs is nearly always impaired; 
- these changes together lead to a higher free plasma level of 
drug; 
- as no consistent pattern is reported in the change in receptor 
number and affinity, this must and does lead to an increase in 
pharmacological effect, if the standard adult dose of a drug is 
given to old people. 
Diuretics are frequently prescribed to the elderly (7). Most 
diuretics are thought to exert their saliuretic effect from the 
luminal side of the renal tubule (4). This means that diuretics 
act after renal excretion! Fig. 2 illustrates the consequences 
of this particular site of action on the changes that are to be 
expected in old age: if the renal excretion of diuretics is 
lessened in old age, one might expect that their saliuretic effect 
is not increased, but contrary to most other drugs decreased. 
The objectives of our study were: 
- are the changes reported in the handling of other drugs by the 
elderly, applicable to a diuretic as well? 
- is there a change in effect induced by tolerance, old age or 
disease? 
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D 
V D S S 0.11-0.21 l/kg 
tVaa 10-20 m i n M 
total b o d y clearance 
150-200 m l /mi η 
3 0 - 7 0 % E renal c learance 95-135 m l / m i η 
/ 
ι 
r e c e p t o r i 
e f f e c t 
Л. Pharmacokínetios of furosemide in healthy volunteers 
FUROSEMIDE OLD 
V D S S 0.12-0 .25 l /kg 
tV2a 10 -Д0 m i n M 
total body clearance 
40-120 m l / m i n 1 
3 5 - 5 0 % E renal clearance 2 0 - 6 5 m l / m i n 
У 
f 
r e c e p t o r 
e f f e c t 
4. Pharmaookinetbcs of furosemide in the old patients studies 
- can we predict or explain the extent of the saliuretic effect 
in a specified patient? 
We choose furosemide as our model-substance. 
MATERIALS AND METHODS 
Furosemide is the far most prescribed drug in old people in 
The Netherlands. We studied the pharmacokinetics and pharmaco­
dynamics of furosemide (F) in patients over seventy, who used the 
drug for more than three months, many of them for years, in the 
treatment of congestive heart failure. Details about the patients 
will be published elsewhere (15). 
On the first day of the study the patients ingested their 
normal F dose orally, and the recovery of F and its glucuronide 
were measured with an HPLC method (16). One week later we injected 
40 mg of F intravenously and collected blood and urine from 
fourteen patients, one healthy young male volunteer and from an 
old volunteer. Drug levels and effects were measured (F and F-gluc 
concentrations, volume of urine, sodium and chloride concen­
tration) . 
The pharmacokinetics (1,2) and pharmacodynamics of F in young 
healthy volunteers are well-known, so we did not repeat these 
experiments. A synopsis of these pharmacokinetic data is given in 
Fig. 3, a summary of these pharmacodynamic data in Table 1. 
To construct individual dose-response curves we used the 
renal F-excretion rates as the dose, and the fractional chloride 
clearances attained as the response. 
The renal F-excretion rate, calculated in each urine sample, is: 
F concentration χ volume/interval between voiding. 
The fractional chloride clearance, also calculated in each urine 
sample, is: 
urinary cone, of CI in each sample apart (i) /plasma CI cone. 
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TABLE I 
Literature-data about furosemide effects in healthy volunteers 
(not all studies are mentioned) 
Author 
Cutler6 
Gonzalez 
Homeida 
.11 
Honan 
τ · 12· Irvin 
Kaojarern 
Keller'4 
17 Rupp 
D l 8 Rupp 
Smith 
dose 
(mg) 
АО 
40 
40 
1 mg/kg 
40 
40 
40 
40 
40 
40 
40 
methods 
i .v. 
i.v. 
i.v. 
i.v. 
oral 
i.v. 
i.v. 
i.v. 
oral 
i.v. 
i.v. 
+ 
-
+ 
+ 
-
+ 
+ 
-
-
-
_ 
age 
(years) 
15-44 
19-46 
20-25 
-
22-34 
-
20-45 
-
-
-
21-33 
excretion of 
urine(ml) sodium(mirinl) 
5900+1500 
1600+50 
2688+326 
5098+64 
1700 
-
4657+694 
1750 
1600 
1900 
2257+422 
— 
647+233 
194+58 
258+21 
578+64 
190 
360+43 
313+75 
215 
220 
-
291+53 
time" 
(h) 
0-6 
0-5 
0-6 
0-6 
0-8 
0-6 
0-4 
0-4 
0-6 
0-4 
0-8 
** 
) + means with replacement of urinary loss of water and electro­
lytes 
- means without replacement 
) after 6 to 8 hours the effects of an oral dose are nearly 
identical to the same intravenous dose (17,2,3) 
(mean of three measurements) divided by 
urinary cone, of creatinine in each sample apart(i)/plasma creat. 
cone, (mean of thregnmeasurements) 
in formula: F
r 1" 
ге, .measurements) 
PciT] [u
 t .] 
1
 i J : l creat. ν 1
 [ РСГ] Pcreat ] 
In this way 7 to 15 data points (including a sample before 
injection) were available in each individual describing the dose-
response relationship. 
We used this fractional clearance to correct for the decrease 
in glomerular filtration in the elderly. We used chloride because 
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Fig. 5. Relation between plasma urea and renal furosemide clearance (CV ) ; 
the open doi represents the same data in a young volunteer, the half-closed 
dot in an old volunteer (75 years) 
C l ^ ( m l / m i n ) 
100-1 
8 0 -
6 0 
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η =15 
г = + 0.85 
p< 0.0005 
2 0 ДО 60 80 100 120 
E CC. ( m l / m m ) 
Fig. 6. Relation between endogenous creatinine clearance (ecc) and (CV ) ; 
the open and half-closed dot have the same meaning as in Fig. 5 
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it is less extensively absorbed in the distal parts of the renal 
tubule (F acts at the luminal site of the thick ascending limb of 
Henle's loop by inhibiting sodiumchloride transport (2,5)). 
RESULTS 
Pha гшас okinetics 
In Fig. 4 the results of the analysis of the pharmacokinetic 
data are summarized. The absorption seemed slightly decreased, 
the volume of distribution was increased only in the patients 
with low plasma protein levels. Total body clearance and renal 
clearance were markedly less; the elimination half-life therefore 
was prolonged. Full details about the individual results will be 
published elsewhere (15). 
Dose-Response Relationship 
In Table II the individual results of the furosemide excre­
tion rate and the fractional chloride clearance achieved are 
given. We think that the following conclusions are justified: 
- in general the maximuro effect of F is less in the elderly, 
caused by a decreased renal F-clearance; 
- no clear-cut tolerance or resistance to F is apparent provided 
that F can reach its site of action (is secreted). 
Relation between Patient-characteristics and Effects 
As argued before, the effect of F is determined by its renal 
clearance (CI ), so we sought for parameters to predict this 
r
 . f 
renal clearance. There was some relation between CI and plasma 
f r 
uric acid, between CI and plasma creatinine. The best correla-
. . Τ . f 
tions are visualized in Fig. 5 and 6 between Cl and plasma urea, 
f . . r 
and between CI and the endogenous creatinine clearance (ecc). 
In the clinical situation the maximal size of action of F can 
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TABLE II 
Individual Dose-Response Relations: The values of FCC in the 16 
individuals (A, B, patient 1-14) are given in relation with the 
individual's F-excretion rate values throughout the first eight 
hours 
. 
c 
• H 
в 
00 
д. 
ω 
и 
СО 
и 
с 
О 
и 
2 
и 
0) 
1 
PL, 
1% 
13 
13 
.30 
25 
10 
33 
10 
20 
10 
40 
25 
— 
25 
20 
10 
10 
Fractional Chlorid 
2.5% 5% 7.5% 10% 
20 35 55 65 
20 30 40 65 
30 40 50 85 
15 20 30 50 
55 
15 25 40 50 
25 40 50 70 
30 55 80 100 
60 100 200 
45 75 100 130 
40 70 120 
40 55 75 90 
35 75 140 180 
15 25 30 45 
20 70 
e Clearance 
12.5% 
80 
130 
90 
90 
80 
150 
160 
130 
55 
15% 
95 
130 
180 
200 
80 
20% 25% 30% 
130 190 300 
250 
100 130 
A 
В 
~"l 
2 
3 
4 
5 
6 
7 
" 8 
9 
10 
II 
12 
13 
14 
be feared, so we sought for parameters to predict this maximal 
diuresis. The parameters which suited best are depicted in Fig. 7 
and 8. Visual interpretation of Fig. 7 and 8 suggests a clear but 
non-linear relation between the individual's tendency to retain salt 
(low basal clearance of sodium or chloride) and a decreased effect of 
F-injection. This relation is inadequately analysed with linear 
regression (although even than ρ < 0.05); obviously too few data 
points are available for more sophisticated non-linear regression 
analysis. Again there was a connection between the ecc and this 
effect of F. 
Apart from a peak-effect on diuresis, the overall effect of 
an F-injection is wanted. This effect, which occurs within the first 
volume ( I ) 
80 100 120 
E CC (ml/min) 
EFFECTS OF FUROSEMIDE IV 
Fig. JO. Cumulative effect of 40 mg 
furosemide in the first four hours after 
i.V. injection, arranged according to 
individual eco of the patients. The standing 
bars represent volume voided, the hanging 
bars represent both sodium excretion and 
0
 chloride excretion (in mmol). In most 
patients chloride excretion exceeded sodium 
excretion so the total hanging-bar length 
represents the chloride excretion attained, 
the shaded part of it depicts the sodium 
200
 excretion (in two patients sodium excretion 
I exceeded chloride excretion). The inter-
uvNa* rupted bar on the right of the figure 
represents the effects in a young volunteer, 
to illustrate the decrease in diuretic 
effect of F in the elderly 
v o l u m e ( I ) 
100-
UVC|-(mmo( ) 
η =14 
г = ΟΘΟ 
ρ < О 001 
er 
г =0 80 
ριΟΟΟΙ 
40 
Na 
г = 0 79 
р<0 001 
100 
2 0 0 
U V N a ' (mmol) 
60 ΘΟ 
С І ^ ( m l / m m ) 
Fig. 11. Cumulative effect of 40 mg furosemide in the first four hours after 
i.V. injection, arranged according to individual renal F-clearance of the 
patients; see also legends of Fig. 10 
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four hours after injection was also classified according to simple 
patient-characteristics. Fig. 10 gives the result of arranging 
F-effect according to the individual's ecc. 
The best prediction of the effect of an F-injection is 
possible if the renal clearance of F is known (Fig. 11). Useful 
seems the relation between plasma creatinine and effect, of course 
this relation is not totally unexpected. 
The results of F-injection to a young healthy volunteer are 
also depicted in Fig. 10 and 11 (as an interrupted bar), to show 
the decrease in effect in all geriatric patients; the results of 
others, summarized in Table I, support this observation. 
DISCUSSIONS 
The normal changes in pharmacokinetics in old age, hold for 
F as well. The proposed adaptation (Fig. 2) of the WHO-diagram 
(Fig. 1) if diuretics are concerned, with transposition of 
receptor and effect to excretion route instead of plasma level, 
seems valid. If the decrease in renal function is taken into 
account, the pharmacodynamics of F in old age are not dramatically 
changed. Finally the decreased effects of F can to a modest degree 
be explained or predicted by simple patient-parameters like the 
ecc. 
Old people tend to be protected to the brisk diuresis, 
usually following F-injection. Only those with the best conserved 
renal function are at risk for too prompt and too extensive 
diuresis. The clinical prudence in "dosing low in old people" 
does not apply to F. If an indication for treatment with a high-
ceiling diuretic exists, the normal dose can and should be given, 
occasionally a larger one. 
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PHARMACOKINETICS AND PHAKMACODYNAMICS OF FUROSEMIDE IN AGED PATIENTS 
A.L.M. KERREMANS, Υ. ΤΑΜ, H. van BAARS, C.A.M, van GINNEKEN and 
F.W.J. GRIBNAU 
SUMMARY 
Furosemide is frequently used by old people in various chronic diseases. 
We wanted to know whether age-related changes in the disposition or the effect 
of F occurred,and whether these changes could be predicted or explained. 
Pharmacokinetics and diuretic effect were studied after intravenous F 
injection in geriatric patients (70-93 years old). The changes in pharmaco­
kinetics were: slightly enlarged volume of distribution (V,, 0.16 + 0.0A 1/kg) 
Dss — 
inversely related to serum albumin, diminished total body clearance 
(73 + 27 ml/min), decreased renal clearance (40 + 18 ml/min) and elimination 
half-life therefore prolonged (180 +_ 87 min). F effects were unchanged only if 
the decreased renal delivery of F and the decreased glomerular filtration rate 
were taken into account. 
The renal F clearance correlated best with the endogenous creatinine 
clearance (ecc, ρ < 0.001) and with F effects (p < 0.001). Only the ecc and 
plasma creatinine turned out to be useful patient characteristics to predict 
all F effects. 
Many drugs have an increased effect in the elderly, based on higher free 
plasma levels attained, if a standard dose is used. In the case of F, however, 
the effects were lessened because they depend on decreased glomerular 
filtration of electrolytes and water, and on decreased renal F secretion. 
These decreased are partly age-dependent, in part disease-dependent. 
INTRODUCTION 
Most pharmacokinetic studies are done in healthy, young, predominantly 
male volunteers given a single dose of a single drug. Most drugs are used by 
not too healthy, old, predominantly female patients, treated on a chronic basis 
with multiple drugs. In old age, changes in pharmacokinetics occur. The 
absorption of drugs is generally unchanged, their metabolism sometimes 
decreases and the excretion almost invariably lessened 
Pharmacodynamic data during chronic therapy are scarce, especially in the 
99 
aged, although it is thought most likely that the number and affinity of 
receptors change during long-term treatment with, say, B-adrenoreceptor 
19 27 . . 
blocking drugs or ß2-adrenoreceptor-stimulating drugs . Drug-specific 
23 
tolerance is described, e.g. to the effects of hydralazine and glyceryl 
21 
trinitrate . We decided to study these problems using furosemide (F). F is 
the drug most widely prescribed to old people in The Netherlands; it is used 
chronically and its kinetics and dynamics are easy to measure in a short time, 
so that very old people can be studied without substantial discomfort. F is a 
potent diuretic drug, frequently used in patients with congestive heart 
failure and cor pulmonale. In healthy volunteers, oral F absorption is 
reported to be 30-84%, volume of distribution 0.07-0.18 1/kg, elimination 
2 9 
half-life (B-phase) 30-70 min, total body clearance 120-200 ml/min ' . F is 
highly protein-bound and is secreted into the tubular fluid in the proximal 
tubule by the organic anion transport system . F exerts its action on the 
luminal side of the thick ascending limb of Henle's loop by inhibiting 
fi 7 "λ 
chloride transport ' or by inhibiting sodium/chloride co-transport . The 
diminished effect of F sometimes observed in clinical cases could be due to 
22 . 4 
altered pharmacokinetics , altered pharmacodynamics , or both. Apart from 
this, compensating mechanisms in the distal renal tubule could play an 
important role and so could changes in extracellular fluid volume, as 
. 12 described for thiazides and ethacrynic acid 
Our study aimed to answer some of these questions and to see whether the 
effects of F could be predicted or explained from simple patient parameters. 
We found the changes in kinetics that are expected in old age; with other 
drugs these changes lead to higher free plasma levels and enhanced pharmaco­
logical effect. In the case of F the diminished renal excretion led to a 
diminished effect. 
SUBJECTS, MATERIALS AND METHODS 
Subjects 
Table I lists details on the patients participating in the study. We 
included one young (A) and one old (B) volunteer for comparison. All patients 
used F for at least three months, and most of them used other drugs as well; 
these other drugs were continued during the study. The research protocol was 
approved by the local committee on human research. 
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Research protocol 
OralFstudy: Interi patients 24-hour urine was collected (in opaque plastic 
bottles containing 5 mg КОН 10%) after ingestion of the individual's normal 
daily F dose: to gain some impression of the bioavailability of furosemide, to 
measure the ecc and to see whether intravenous F injection was safe. 
Intravenous F study: Patients had breakfast at the normal time, were 
allowed to eat and drink as usual; during the morning they stayed recumbent. 
They were asked to void after the night, and this urine was discarded. At about 
9.00 A.M. blank urine was sampled. Immediately thereafter blood was drawn from 
a forearm vein for determination of minerals, albumin, aldosterone,hemoglobin, 
hematocrit, urea, creatinine, uric acid, and to obtain a blank F sample. Then 
40 mg F was injected intravenously within one minute (only the old volunteer В 
received 20 mg). After 10,20,40,60,90,120,180,240,360 and 480 minutes, blood 
was sampled by venipuncture for determination of plasma F levels; at 120 and 
480 minutes, plasma minerals and creatinine were also measured. For the first 
eight hours after injection, urine was voided and collected as frequently as 
possible. Six to fifteen samples were obtained in this way. The samples were 
1 8 
carefully protected from light . The urine voided 8-24 hours after injection 
was stored as in the oral F dose experiment. Blood pressure and heart rate 
were frequently measured before and during the eight hours after the F 
injection. 
Measurements 
After measuring the volume of urine the following concentrations were 
determined: sodium by standard flame photometry with lithium as internal 
о 
standard, chloride by a semi-automatic coulometric titration procedure , 
creatinine by a photometric continuous flow procedure based on the Jaffé-
reaction with alkaline picrate. The absence of proteinuria was checked with 
Albym-test sticks (Boehringer Mannheim, FRG) F and F-gluc were determined by 
1 8 
an HPLC method . In the blood samples sodium, chloride, F and creatinine were 
measured as described above; bicarbonate, urea, uric acid, hemoglobin and 
hematocrit were measured by standard laboratory procedures. Albumin was 
determined with a manual bromcresol green method, aldosteron with a RiA-
-l, J 2 0 
method 
Pharmacokinetic analysis 
The plasma F concentrations were subjected to computerized pharmaco-
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kinetic analysis with the aid of the non-linear regression program for curve-
fitting FARMFIT, in use at the Computer Center of the University of Nijmegen. 
A two-compartment open model was used. The regression analysis yielded optimal 
results, among others, of tla, ti6, V„ , AUC, CI ,,. V . The renal excretion 
'
 e
 Dss ' all' с 
rate of F (Rr) was calculated by multiplying the measured F concentration in 
every urine sample by its volume and dividing that by the time during which 
the sample was made, in equation Rr = Fconc χ volume/time. Renal F clearance 
(CI ) was calculated in two ways, using dose recovered in the urine (Du) 
divided by the AUC 
CI (1) = Du/AUC 
and by calculating it for each sample period separately, dividing R by the 
actual plasma concentration of F (Pf) 
Cl
r
(2) = Rr/Pf. 
V area was calculated as Dose. tJß/AUC.ln2. 
Pharmacodynamic analysis 
In view of the supposed action of F we used the following items in our 
dose-response studies. As a measure of the effective dose we used R (ug/min), 
because it is impossible to measure or calculate the F concentration in 
Henle's loop in man. As response we used the voided quantities of water, sodium 
and chloride during the first four hours after injection, the maximal urinary 
output (volume) and F-,.-: the fraction of the chloride load filtrated in the 
glomeruli that was excreted in the urine. The glomerular filtration rate was 
estimated with the aid of the ecc, so the equation used for F_1- was: 
[Cl-jurine . [creatinine] u 
CI ^Cl-Jplasma ' [creatinine] ρ 
The same adapted equation was used in calculating F +. 
All variable data are given as mean with standard deviation and range. 
Linear regression lines were calculated (method of least squares) if assumption 
of linearity was thought suitable after graphic representation of the data. To 
test correlations between patient variables, drug levels and effects, we used 
the first four hours after F administration. 
Student's t test was used to test statistical significance. 
RESULTS 
Pharmacokinetics 
In ten patients the 24-hour recovery of F and F-gluc together was 39 + 9% 
(range 22-50%) of the dose ingested. After intravenous injection this recovery 
103 
was 7 0 + 1 1 % (51-84%). Only 0-10% of the oral F dose could be recovered in 
the urine as F-gluc, probably due to decomposition to F despite our 
precautions. In the intravenous study 1 7 + 4 % (9-28%) of the dose was 
recovered as F-gluc. No trace of the controversial metabolite 4-chloro-5-
sulphamoylanthrani1ic acid was found. The individual kinetic results of the 
intravenous study are shown in table II. 
TABLE II 
INDIVIDUAL PHARMACOKINETIC DATA AFTER I.V. F ADMINISTRATION 
patient 
A 
В 
1 
2 
3 
4° 
5 
6 
7 
8 
9° 
10° 
11 
12 
13 
14 
tia 
min 
17 
10 
24 
32 
32 
30 
6 
21 
42 
27 
23 
18 
# 
* 
42 
min 
67 
91 
136 
203 
114 
317 
108 
142 
267 
235 
166 
300 
143 
59 
110 
234 
v
c 
1/kg 
0.08 
0.07 
0.11 
0.08 
0.10 
0.09 
0.04 
0.10 
0.11 
0.09 
0.07 
* 
0.07 
* 
* 
0.10 
VDss 
1/kg 
0.14 
0.16 
0.18 
0.17 
0.19 
0.18 
0.12 
0.18 
0.17 
0.23 
0.13 
* 
0.13 
* 
* 
0.18 
v 
Darea 
1/kg 
0.26 
0.19 
0.26 
0.32 
0.28 
0.16 
0.16 
0.21 
0.43 
0.35 
0.23 
0.49 
0.14 
0.13 
0.27** 
0.25 
ci
r
(i) 
ml/min 
81 
60 
30 
45 
60 
12 
26 
35 
35 
60 
36 
43 
22 
65 
70** 
21 
Cl
r
(2) 
ml/min 
85+23 
61 + 17 
42+25 
50+9 
61+26 
14+2 
25+8 
36+6 
36+14 
63+1 1 
42+21 
57+42 
25+13 
69+26 
70+27 
22+9 
C 1
 11 
all 
ml/min 
218 
107 
103 
113 
102 
29 
62 
75 
67 
74 
42 
74 
62 
86 
118** 
46 
CI 
r 
C 1
 11 
all 
0.37 
0.56 
0.29 
0.40 
0.59 
0.41 
0.42 
0.47 
0.52 
0.81 
0.85 
0.58 
0.36 
0.75 
0.59** 
0.46 
AUG 
mg/min/l 
314 
192 
394 
368 
399 
1375 
605 
539 
588 
554 
947 
541 
672 
369 
340** 
849 
CI (1) and CI (2) according to the equations in the text. 
* It was impossible to estimate a reliable tjCt and V in these patients. 
** Assuming that CI (1) = CI (2). 
These patients had residual concentrations at the time of injection. 
Kinetic analysis was adapted accordingly by incorporating the residual 
concentrations in the central and periferal compartment into the boundary 
conditions of the two-compartment open model. 
In our group of patients the mean values of the parameters were t|a 
2 6 + 5 minutes, tjB 180 + 87 minutes, V 0.09 + 0.02 1/kg, V D 0.16 + 0.04 1/kg, 
V^ 0.26 + 0.10 1/kg, CI ,. 73 + 27 ml/min, CI 40 + 18 ml/min. The fraction 
Darea — ь ' all — r — 
of total body clearance proceeding via renal F excretion (the elimination route 
leading to a diuretic effect) varied nearly threefold from 29-81%. 
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Relation between patient charachteristics and F-kinetics 
13 Since we agree with the question of Greenblatt et al. , we calculated 
V_ as well as V^ . These V,, data were clearly correlated inversely Darea Dss Darea ' J 
with the serum albumin levels (r =-0.74 ρ < 0.01). In our data t|3 related to 
the ecc (r = -0.63, ρ < 0.05). Because the effect of F depends largely on the 
amount of F excreted renally, we tried to establish which simple patient 
parameter correlated best with CI (1). The following relations were found: 
between CI (1) and plasma uric acid (r = -0.59, ρ < 0.05), plasma urea 
(r = -0.72, ρ < 0.01), plasma creatinine (r = -0.74, ρ < 0.01) and ecc 
(r = +0.85, ρ < 0.001). 
In search of a simpler patient parameter than the classically measured ecc, we 
1 ft 
used the nomogram of Kampmann et al. . This nomogram approximates the ecc on 
the basis of plasma creatinine, age, sex and body weight. The "ecc" values 
obtained in this way correlated well with measured ecc values (r = 0.83, 
ρ < 0.001) and were equally useful in the prediction of CI (1) (with r = 0.86, 
ρ < 0.001). Plasma creatinine in our data had surprisingly an even worse 
relation with the ecc (r = 0.50) than plasma urea (r = 0.65) had. 
Pharmacodynamics 
During the intravenous study there were no consistent changes in plasma 
sodium, chloride and creatinine. The mean change in systolic blood pressure 
was -6.2 -f 6.9% (range -18% to +9%, rise in two patients, unchanged in one) 
after two hours. At that time the patients were still in a recumbent position. 
The mean change in diastolic blood pressure after two hours was +0.27Z + 8.0% 
(decrease in three patients and B; range -16% to +8%). Within four hours the 
increase in urine output induced by F was over. The volume voided in this 
period ranged from 190 to 1900 ml, sodium excretion ranged from 2 to 225 mmol 
and chloride excretion from 7 to 250 mmol. In the 24 hours following injection 
the effects were: volume 800-2500 ml, sodium 6-260 ml, chloride 9-280 mmol. 
The calculated maximal urine production rate ranged from 1 to 16 ml/min. The 
F - rose to 10-30% of the glomerular filtrate. The individual data are 
summarized in table III. 
Figure 1 gives the relation between furosemide excretion rate and F
r 1-. 
For all patients (except patient eight) and volunteers the rise in F...- from 
1 to 5% took place in the excretion range from 10 to 75 yg/min. Combining 
table III and figure 1, we find that the small effect of F in patients one and 
four was due mainly to excretion of marginal F amounts in the urine. The 
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relation between plasma F levels and effects was intraindividually just as 
good, but interindividually more diversion in dose-response relation occurred, 
especially in the lower effect range (e.g. F - of 2% took place at plasma F 
levels from 0.3 to 3.2 mg/1, and F - of 10% occurred at plasma levels from 
CI 
0.95 to 3.3 mg/1). 
TABLE III 
INDIVIDUAL PHARMACODYNAMIC DATA AFTER 
patienl 
A 
В 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
F
«
 + l 0
"
3 
Na blank max 
5 
2.0 
0.3 
0.5 
1.0 
0.3 
0.6 
0.2 
0.3 
0.2 
0.6 
0.9 
0.4 
1.9 
1.8 
0.5 
167 
56 
7 
86 
85 
5 
66 
91 
129 
54 
120 
53 
70 
53 
201 
30 
F
cr
 10
"
3 
blank max 
10 
5 
0.5 
0 
0.4 
0 
1.0 
0 
0.8 
0 
0.1 
1.0 
0 
3.8 
2.7 
0 
322 
96 
15 
135 
132 
27 
133 
161 
190 
71 
182 
79 
126 
103 
292 
47 
Ka+0-4 h 
mmol 
220 
70 
7 
I.V. F ADMINISTRATION 
Cl 0-4 h 
mmol 
270 
90 
12 
70 85 
110 ι 115 
2 ' 7 
55 ' 75 
50 ' 70 
70 i 75 
105 i 100 
95 ' 90 
145 150 
45 60 
85 115 
225 
25 
250 
30 
diuresis 
ml 
1950 
740 
250 
830 
1100 
190 
750 
750 
670 
1250 
780 
1250 
840 
970 
1900 
640 
maximal urine 
production ml/min 
26 
14 
2 
9 
15 
1 
13 
7.5 
8.5 
10 
10 
12.5 
8.5 
16 
15 
6 
Relation between patient characteristics and dynamics 
There was some correlation between the voided volume of urine (0-4 hours) 
and plasma creatinine (r = -0.61, ρ < 0.05), ecc (r = 0.62, ρ < 0.05) and blank 
F + (г = 0.64, ρ < 0.05). Similar correlations were found between sodium 
excretion (0-4 hours) and plasma creatinine (r = -0.66, ρ < 0.05) and blank 
F + (r = 0.66, ρ < 0.05). The chloride excretion (0-4 hours) had some 
relation with ecc (r = 0.60, ρ < 0.05), basal F - (r = 0.60, ρ < 0.05), plasma 
creatinine (r = 0.61, ρ < 0.05) and with blank F + (r = 0.74, ρ < 0.01). The 
maximal effect on diuresis correlated with blank F .- (г = 0.64, ρ < 0.05), 
with blank F + (r = 0.74, ρ < 0.01) and with the ecc (r = 0.70, ρ < 0.01). The 
Na 16 
ecc' calculated with the use of Kampmann's nomogram proved to be a useful 
simple tool in predicting F-effects in the first four hours after injection: 
the coefficient of correlation of "ecc" with peak effects was r = 0.69 (p < 0.01), 
with total diuresis r = 0.75 (p < 0.01) with sodium excretion r = 0.74 (p < 0.01) 
and with chloride excretion r = 0.76 (p < 0.01). 
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individual dose-response 
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response ; letters and 
numbers refer to tablfi T. 
As c o u l d be e x p e c t e d , t h e r e l a t i o n b e t w e e n CI and e f f e c t was good f o r 
volume ( r = 0 . 8 0 , ρ < 0 . 0 0 1 ) , sodium e x c r e t i o n ( r = 0 . 7 9 , ρ < 0 . 0 0 1 ) , c h l o r i d e 
e x c r e t i o n ( r = 0 . 8 0 , ρ < 0 .001) and peak e f f e c t ( r = 0 . 7 0 , ρ < 0 . 0 1 ) . Not 
s u r p r i s i n g l y i n v iew of t h e supposed i n t r a t u b u l a r e f f e c t of F , an i n v e r s e 
c o r r e l a t i o n e x i s t e d be tween t h e AUG and e f f e c t , e . g . on w a t e r d i u r e s i s (0-4 h ; 
r = - 0 . 7 0 , ρ < 0 . 0 1 , η = 13, w i t h t h e n o n - r e s p o n d i n g p a t i e n t 1 l e f t o u t ) . 
DISCUSSION 
Des ign 
Our s t u d y i n t e n d e d t o d e s c r i b e t h e e f f e c t s of a d r u g o b s e r v e d i n e v e r y d a y 
c l i n i c a l p r a c t i c e ; t o t r e a t o l d p a t i e n t s , i n s t e a d y s t a t e c o n d i t i o n s and used 
i n c o m b i n a t i o n w i t h o t h e r d r u g s . We t h e r e f o r e had t o s t u d y t h e a v e r a g e p a t i e n t , 
w i t h a l l h e r ( ! ) many u n c e r t a i n t i e s and c o - f a c t o r s and n o t t h e s i m p l e , c l e a n , 
1 0 7 
easy to handle, single-dosed volunteer. Tn describing the influence of "age" 
9 
Cutler could only refer to studies on neonates and infants. We had to make 
one change in everyday practice: we injected the drug (F) to enable more 
conclusive pharmacokinetic studies. Although it was not our intention to do 
oral studies we did so, preceding the intravenous F injection, at a suggestion 
of our ethics committee. Clinical reports on F effects describe mostly patients 
with acute pulmonary edema or ascites. As far as we know, only two patients 
2 
described in the literature are comparable with ours: patient E , a 72-year-
old man using 80 mg F daily for at least four days previously, with congestive 
4 heart failure and coronary artery disease, and patient ΚΑ , an 83-year-old 
black woman using 40 mg F daily combined with digoxin and quinidine for hyper­
tensive and atherosclerotic cardiovascular disease. 
The pharmacokinetic results in patient E differed from the mean in his 
fellow-patients: longer tjß, larger V , lower total body clearance. The 
pharmacokinetics in patient KA are not given. 
Analysis 
The accurate handling of biological samples containing F remained 
difficult; although we succeeded in preventing the photochemical degradation 
1 8 
of F , the alkaline hydrolysis of F-gluc back to F remained a problem, 
We analyzed our plasma level versus time curves using a two-compartment 
open model, not with the three-compartment model as proposed by Rupp ; our 
data fitted very well in the simpler model, not better in the three-
compartment model. Apart from this, the supposed γ-phase of F elimination is 
pharmacodynamically irrelevant in any case: the effect of F has long dis­
appeared. We related the effect of F to the ecc of the patients: ten percent 
of a glomerular filtration rate of 180 1/day is clearly of a different order 
of magnitude than ten percent of 50 1/day. Recently the active chloride 
transport in the thick ascending limb of líenle's loop has been questioned, and 
3 
a sodium chloride co-transport has been proposed (for review, see C. Berry ). 
We think that the "fractional chloride clearance" we used is a good parameter 
of F effect in man, because sodium reabsorption can be considerable in more 
distal segments of the nephron especially, if in the course of diuretic 
treatment the renine-angiotensine-aldosterone system becomes activated. In 
patient number 4 we saw in fact no effect of r on sodium clearance but 
definitely an effect on chloride clearance. Addition of spironolactone to 
this patient's diuretic regimen resulted in sodium excretion too. 
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Pharmacokinetics 
13 
In essence the changes of pharmacokinetics in old age are known . We 
found the same trends: absorption virtually unchanged, volume of distribution 
nearly unchanged, total body clearance reduced and renal clearance declined. 
In the case of F too these changes led to increased plasma levels and 
increased AUG. The V_ correlated inversely with the plasma protein level; 
Darea J 
this relation did not reach significance using V (thought a slightly 
inferior parameter if drugs are studied after intravenous injection ). 
Urinary recovery of F was always below a hundred percent, with various 
ratios between F-gluc and active F. 
Pharmacodynamics 
In general the pharmacokinetic changes occurring during aging lead to 
higher free plasma levels of a drug, an enhanced peak effect and a longer 
lasting effect. A special effect of diuretics is that kinetic changes leading 
to a higher free plasma drug level in old age, do not cause an increased 
effect. On the contrary, these drugs act after excretion into the renal tubule 
(by glomerular filtration but mainly by tubular secretion). In old age both 
glomerular filtration rate and tubular secretion decrease ' . In congestive 
heart failure (CHF) renal blood flow is diminished and a correlation between 
the decrease in left ventricular ejection fraction and fall in ecc has been 
demonstrated . The effect of diuretics in CHF patients is therefore reduced 
out of proportion by two mechanisms as demonstrated in our patients: firstly, 
1 24 less drug is available in the renal tubule (by impaired tubular secretion ' ), 
and secondly there is less "substrate" present to act upon (by impaired 
12 
glomerular filtration and augmented proximal tubular reabsorption of water 
and electrolytes). 
We did in fact find these trends: the renal excretion of F was diminished 
according to the decline in ecc; the effects of a given F amount in the urine 
were unchanged only if calculated as a fraction of the ecc. 
The decreased clinical response to F injection that we found could be 
explained by these two factors. We did not find clear resistance to the effects 
of renally secreted F in this group of long-term F users. The short elimination 
half-life of F may be an explanation: with single daily doses the renal tubule 
is exposed to F for a limited time. Contrary to these considerations one might 
speculate that, if less furosemide is secreted into less glomerular filtrate, 
the F concentration at the receptor site might be unchanged but nevertheless 
leads to less effect, as we found, thus leading to the conclusion that 
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tolerance exists. 
Correlations 
The inverse correlation between AUG and F effect supports the opinion 
that plasma levels of diuretics have no direct and simple relation to effect. 
The most simple parameters (body weight, plasma urea or creatinine, urinary 
sodium or chloride concentration) were unsuitable Lo predict F effects. 
Somewhat more sophisticated methods were useful however: the measured ecc but 
1 ft 
also the "ecc" as derived from body weight, age, sex and plasma creatinine 
correlated quite well with effects. A problem remains the unpredictability of 
non-renal F clearance. 
CONCLUSION 
Many drugs have an increased effect in the elderly, based on higher free 
plasma levels attained, if a standard dose is used. In the case of F, however, 
the effects were lessened because they depend on decreased glomerular filtration 
of electrolytes and water, and on decreased renal F secretion. These decreases 
are partly age-dependent, in part disease-dependent. 
Aged people have a vulnerable circulatory homeostasis. High-ceiling 
diuretics with a prompt onset of action place them at risk of acute hypovolemia. 
To some extent the aged patient is protected from these circulatory effects of 
F in a standard adult dose as a consequence of an age-related decrease in renal 
function. In fact no age-related increase in F side-effects was reported from 
14 
the Boston Collaborative Study . Obviously aged people with only slight 
impairment of cardiac and renal function are especially at risk of hypovolemia. 
Tailoring the F dose by anticipation remains difficult: effects can be 
insufficient or drastic. A general advise to use lower starting and maintenance 
doses in the elderly with CHF is unnecessary if diuretics are concerned, that 
have their site of action in the renal luminal compartment. 
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URINARY PROTEIN BINDING OF FUROSEMIDE 
a brief report on some pilot experiments 
A.L.M. KERREMANS, H.J. CREMERS, J.F. RODRIGUES DE MIRANDA 
SUMMARY 
We investigated the possible role of urinary protein binding of furosemide 
(F) in the emergence of diuretic resistance in the nephrotic syndrome. Protein 
binding of F was studied using equilibrium dialysis under conditions probably 
present in the tubular urine. We also studied pharmacokinetics and pharmaco-
dynamics of F in three proteinuric patients (4-9 g albuniin/24-hour urine) , 
including one with hardly treatable diuretic resistance. A single F-displacing 
experiment with sulfamethizole (S) was performed. Protein binding was less 
avid in urine (20-50% binding) than in plasma or buffer solutions(about 90%). 
The lower albumin levels present in urine were an insufficient explanation of 
this difference. In the diuretic-resistant patient the renal F clearance was 
decreased and the dose-response curve clearly shifted to the right. S had no 
displacing effect on the protein binding of F in our experiment. 
In our opinion urinary protein binding cannot satisfactorily explain F 
resistance in the nephrotic syndrome. 
INTRODUCTION 
In the healthy kidney only minimal amounts of protein are present in the 
glomerular filtrate. In the nephrotic syndrome (NS) large amounts of protein 
can pass through the diseased glomerular membrane, leading to proteinuria, 
hypalbuminemia and edema. Diuretic resistance, e.g. to furosemide (F), is a 
common phenomenon (1,2). F's site of action is at the luminal membrane of the 
ascending limb of Henle's loop (3). In normal subjects F is strongly bound to 
plasma albumin (4), but slightly less in NS (5) and in uremia (6). F reaches 
its site of action mainly via tubular secretion.Generally only an unbound 
molecule can interact with its receptor. Protein binding of F at its site of 
action could explain F resistance in NS (7), because a fraction of F is 
delivered bound to albumin to the collecting duct. It may therefore be worth 
trying to displace F from its urinary protein (albumin). Sulfonamides are 
known to displace F from plasma proteins. Among this group of drugs, sulfa-
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methizole is rapidly excreted in the proximal tubule. We performed pilot 
experiments on the characteristics of the binding of F to albumin in vitro 
under circumstances supposed to exist in the TALH (i.e. 37 C, pH 6-7, ionic 
strength decreasing from + 1000 to + 100 mOsmol). In previous experiments 
urinary F concentrations observed during effect were 4-20 Ug/ml (10-60 yM). 
Looking for other possible explanations of diuretic resistance, we also 
studied the kinetics and dynamics of F in patients with NS, and the effect of 
concomitant S administration. 
MATERIALS AND SUBJECTS 
In-vitro studies 
. 14 
We used a teflon dialyzing cell system with cellulose membranes; C-
labeled F (specific activity 8.4 mCi/mmol, purity > 99%) and unlabeled F were 
gifts from Hoechst AG, Frankfurt, FRG. Other materials used were 0.067 M 
phosphate buffer pH 6.9, with crystalline NaCl added to an ionic strength of 
300 (605) mM; crude human albumin (Sigma, St. Louis, USA); plasma obtained 
from the local blood bank; urine of proteinuric patients. One half of plasma 
or protein-containing urine was ultrafiltrated (Diaflo ultrafiltrating 
membranes YM10 Amicar Corp., Lexington, USA) and served as "buffer" in the 
dialysis experiment with plasma and urine, respectively. After equilibration 
1 ml, taken from every compartment, was dissolved in 10 ml of Instagel 
(Packard Becker, The Netherlands) and radioactivity was counted in a liquid 
scintillation counter (Tri-carb 460CD, Packard Becker, The Netherlands). The 
different in-vitro experiments are listed in Table I. 
The experimental data found were analyzed with FARMFIT (chapter 4.2) 
TABLE I. IN-VITRO EXPERIMENTS 
• • -
exp 
1 
2 
3 
4 
5 
6 
7 
8 
9 
medium 
buffer 
ft 
II 
II 
urine(1) 
plasma 
II 
urine(2) 
" (3)° 
pH 
6.9 
6.9 
6.9 
5.9 
5.9 
7.4-^ 5.9 
7.5^ -6.5 
7.7 7.1 
6.3 
ionic strength 
mOsmol 
300 
605 
300 
300 
-
280 
280 
400 
320 
F 
yM 
3-450 
II 
It 
II 
tl 
3-3000 
3-5000 
3-450 
11 
alb 
8/1
 η 
7 
7 
15 
7 
7* 
17.5 
35* 
9* 
4* 
the numbers refer to the patients described below 
* measured with an (adapted) manual bromaresolgreen method 
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Subjects 
(1) A 66-year-old male with focal glomerulosclerosis, causing proteinuria of 
11-16 g/24 hours; plasma albumin 16 g/1, endogenous creatinine clearance (ecc) 
about 25 ml/min. 
(2) A 66-year-old female with type II diabetes mellitus and proteinuria of 
10-14 g/24 hours, plasma albumin 19 g/1, ecc 25 ml/min, pitting edema and 
ascites. Daily medication used was 750 mg F, 100 mg spironolactone, 75 mg 
indomethacin, 160 mg gliclazide, 10 mg oxazepam, antacid, 1.5 g sodium 
bicarbonate, 30 g sodium polystyrene sulfonate; hemoglobin was 5.6, plasma 
sodium 139, potassium A.5, chloride 104, bicarbonate 30 mmol/1; plasma renin 
activity (pRA) 1.07 pg/ml/h (normal), and plasma aldosterone (pAld), 26 ng/ 
100 ml (slightly elevated). 
(3) A 65-year-old female with type II diabetes mellitus and proteinuria of 
4-7 g/24 hours; ecc 40 ml/min, plasma albumin 38 g/1. Edema had disappeared 
after changing therapy from thiazides to 40 mg F daily; other medication: 
10 mg glibenclamide, 1.5 g Clofibrate, 10 mg oxazepam, antacid, 300 mg allo-
purinol. Plasma sodium 141, potassium 4.1, chloride 101, bicarbonate 26 mmol/1. 
At the first experiment (F), body weight was 62.5 kg and pAld 10 ng/100 ml; 
the values at the second (F+S) were 62.4 kg and 14 ng/100 ml, respectively. 
(4) A 77-year-old female with type II diabetes mellitus, proteinuria of 
1-4 g/day, plasma albumin 33 g/1, ecc 75 ml/min; signs of congestive heart 
failure (CHF) despite treatment with low-salt diet, 80 mg F, and 1/4 mg 
digoxine (I g tolbutamide, vit. В mixture were also used). Plasma sodium was 
144, potassium 2.6, chloride 104, bicarbonate 33 mmol/l. At the first 
experiment body weight was 60.3 kg, pAld 6 pg/100 ml, pRA < 0.3 ng/ml/h, but 
at the second experiment her body weight was 57.8 kg and pAld 50 ng/100 ml; 
signs of CHF had disappeared and plasma potassium was normalized to 4.0 mmol/1, 
all due to addition of triamterene to her diuretic regimen. 
In-vitro binding experiments were done with the urine of patients (1), (2), 
and (3). Pharmacokinetic and pharmacodynamic studies of F were performed in 
patients (2), (3), and (4). Studies of concomitant administration of S and F 
(intending to cause urinary displacement of F from protein) were done in 
patients (3) and (4). 
The kinetic data were analyzed according to a two-compartment open model 
using FARMFIT, the dynamics were visualized in dose-response curves, using 
F excretion rate as the dose and fractional chloride clearance (fCl ) as the 
response (8) . 
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RESULTS 
In-vitro studies 
Equilibrium was attained after dialyzing for 6-8 hours. The pH of the 
buffer and of urine remained constant despite addition of F or albumin during 
dialysis. The pH of plasma fell considerably during dialysis. Since this 
investigation was meant as a preliminary study, we performed no detailed 
analysis of all factors influencing F binding, but only some introductory 
experiments. 
In figure 1 the Scatchard plots of experiments 3 and 6 are depicted, 
showing that F must be bound almost exclusively to albumin and that the 
binding in plasma is comparable with that in buffer solution. 
W Φ 
Figure 2 shows the Scatchard plots of experiments A and 5 ; it can be 
seen that the binding characteristics of F in urine differed vastly from 
those in buffer. 
The binding could be described by a dissociation constant Kd, a number 
of binding sites η and a distribution term (S), as follows: in experiment 3: 
Kd 58 μΜ, η 3, S 0.21 , and in experiment 6: Kd 78 μΜ, η 3, S 0.66 (both in 
figure 1); in experiment 4: Kd 24 μΜ, η 2, S 0.67 and in experiment 5: 
Kd 645 yM, η 5, S 0.00 (both in figure 2). 
BOUND CONC. IN HHOL eOUND CONC.IN ΗΗΠ1 
Fig. 1. Scatchard plots of experiment Fig. P.. Scatchard plots of experiment 
З
ф
 and С' 4 ana 5 . 
The results of our introductory experiments are shown in figure 3. The 
percentage of protein-bound F decreased with decreasing albumin concentrations, 
but in urine an extra decline in protein binding was evident. In the urine of 
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experiment 9 no displacing effect of S on F protein binding could be 
demonstrated. 
F bound (V.) -
100 η 
80 
60 
АО 
20 
albuminf g/D-, 
В \ 
.7 35 ι 
15-17 5 
·« ·-
' -
5
·
β
 -
U
- 7 . 9 
9 
· - A 
ДО 80 120 160 200 240 280 320 360 ¿00 440 
3
,
3
 , 100 total F cone (pM ) 
>jg/nnl pg/mi 
Fiq. Л. Percentual binding of F to protein under different experimental 
conditions in vitro. The numbers refer to the experiments listed in 
Table Ι; В means in buffer or plasma; U means in urine. 
Patients 
The results of the studies in the patients are surranarized in Table II. 
S exerted no clear influence on the kinetics of F, nor did it enhance or 
reduce F effects (patient 3 was the one studied twice under stable conditions). 
Dose-response curves were constructed to detect a possible "shift to the right" 
indicating pharmacological resistance, and to see whether S administration had 
an effect on the characteristics of the curve. The results of patient 4 were 
left out due to the changed hemodynamic conditions of the second experiment, 
and because a second diuretic had to be added meanwhile (all her data points 
were in the neighbourhood of the curves of patient 3 ) . 
The dose-response curves are shown in figure h. 
DISCUSSION 
The in-vitro experiments clearly showed that, as expected, the percentual 
protein binding of F decreased considerably at lower albumin levels. In plasma 
the protein binding was in accordance with what could be expected on the basis 
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TABLE II. PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF F 
KINETICS 
V s ( l i t e r> 
Cl (ml/min) 
CI , (ml/min) 
renal 
Cl
r
/Cl „ 
r
 all . 
AUG mg.min.1 
t|a (min) 
tie ( " ) 
F recovery (%) 
F-gluc recovery (%) 
DYNAMICS 
VOL (0-5h) ml 
VOL (0-24h) ml 
Sodium excr (0-5h) (mmol) 
" (0-24h) ( " ) 
Chloride excr(0-5h)(mmol) 
" (0.24h)( " ) 
patient 2 
250 mg F i.v. 
9.6 
89 
18 
0.20 
2842 
13 
75 
20 
15 
330 
1500 
25 
68 
31 
40 
patient 3 
A 
11.9 
66 
24 
0.36 
607 
30 
147 
35 
1 1 
1370 
2100 
143 
165 
144 
160 
В 
14.6 
78 
28 
0.36 
512 
40 
173 
35 
10 
1470 
2200 
138 
155 
145 
165 
patient 4 
A 
13.6 
77 
50 
0.65 
520 
47 
177 
70 
4 
1330 
1600 
111 
120 
1 13 
150 
В 
11.6 
88 
62 
0.70 
467 
24 
128 
65 
7 
860 
1200 
65 
80 
70 
85 
Л weans 40 mq F i.V.; В means 40 mg F -i.v. and 1 a S orally (one hovr before); 
V^ means volume of distribution in steady state; 
CI ,, means total body olearanae. CI means renal riparante; 
all " r 
AUC is the area under the vlasma level versus time curve; frVa the hal^-life 
of distribution, tbß the half-life of elimination. 
of albumin concentration. In urine, the binding of F to proteins was much more 
impaired than had to be expected in view of the albumin concentrations present. 
The Scatchard plot of the binding of F to proteins in urine indicates a low 
affinity of F for protein and an increased number of binding sites. The 
influence of change in pH or ionic strength was minor; it remains unexplained 
why the binding in urine deviates. It seemed that S did not displace F from 
protein in our single experiment, but even if it should do so, the enhancing 
effect would be small, as most F was already unbound. 
In-vivo experiments showed that the renal excretion of F was not impaired by 
simultaneous administration of S, as could have been expected: both drugs are 
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' Fig. 4. Dose-response curves of 
patient 2(C) and Ъ(А and B). 
A means during F administration 
only, В means during concomitant 
oral S administration; f CI means 
fractional chloride clearance, 
and F excr. rate: the amovnt of 
unchanged F excreted renally 
per minute. 
I I I 1 ' I 1 1 · — 1 I I Ι К 
100 300 1000 
F excr (ug/min) 
secreted by the organic acid pathway into the renal tubule. An explanation 
could be that S displaced F from plasma proteins, and that in this way enhanced 
glomerular filtration of F compensated for hampered tubular F secretion. A 
complete in-vivo displacing experiment under stable conditions could only be 
done in patient 3; no changes were evident. In view of the small percentage of 
F protein binding in her urine, this is not so remarkable. Both patient 2 and k 
had persistant edema despite large doses of F. In patient 2 there was a clear 
shift to the right of the dose-response curve, even in our way of depicting it: 
taking into consideration both the decreased tubular secretion (by using F 
excretion rate as the 'dose') and the decreased ecc (by expressing observed 
effect as a fraction of ecc). The indomethacin she used seemed an insufficient 
explanation of this, if results are analyzed as we did (9); even if her dose-
response curve is corrected for 'free F', it only partially moves up to the 
normal range and the slope remains less steep. Apart from that a remarkably 
high fraction of F was metabolized and not secreted unchanged in the tubule. 
This has struck others too as a possible cause of diuretic resistance (2,10, 
11). In patient 4, addition of triamterene to her diuretic regimen and 
possibly supervision of her low-salt diet were a remedy for her condition. In 
a discussion after a paper presented by Mirkin et al. (12), Anders Rane 
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questioned the validity of the "urinary binding of F" hypothesis to explain 
diuretic resistance in NS. We think that our studies, unfinished and incomplete 
as they are, support his doubts. 
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CHAPTER IX 
SUMMARY AND CONCLUSIONS 
Chapter I of this thesis gives a general introduction to the 
reported studies and poses a series of questions. The problems 
stated will be solved or discussed in this final chapter, and 
the reader is therefore advised to consult the first chapter 
again. 
Chapter II reviews the renal handling of water, sodium chlo-
ride and urate. An overview of the pharmacology of diu-
retic agents is given and the diuretics that have been studied 
(tiemlic acid (TA) and furosemide (F) ) are introduced. 
Chapter III summarizes the actual knowledge about the conditions 
under which the diuretics studied are mostly used. The changes 
occurring in the pharmacokinetics and pharmacodynamics are 
therefore discussed with reference to old age, long-term treat-
ment and heart failure. Elaborating on these themes, the final 
part of this chapter discusses diuretic resistance in congestive 
heart failure; possible means to overcome this problem are pro-
posed. 
Chapter IV highlights the methods used in chapters V through VIII. 
The first section describes the use of the HPLC equipment to 
obtain the data on TA and F concentrations in biological samples. 
Section three discusses the hypotheses, models and methods used 
to process, describe and explain these data (pharmacokinetics). 
The last section is a justification of the complicated method 
we used to analyse the effects of diuretics in relation to their 
concentrations (pharmacodynamics). This chapter also includes 
a section on protein binding of drugs. 
Chapter V summarizes the TA studies and provides answers to the 
first set of questions (a) of the introduction 
- a simple and reliable HPLC-method was developed for determi-
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nation of TA and its alcoholic metabolite, both in plasma and 
in urine 
- the pharmacokinetics of TA were roughly as found in the lite­
rature: small volume of distribution (3-5 1) and low total 
body clearance (about 30 ml/min) : a combination leading to a 
short apparent half-life of elimination (about 2 hours) 
- the uricosuric effect of TA was impressive, increasing the 
fractional urate clearance from about 5% to 30-70%; the natri­
uretic effect of TA was moderate, increasing the fractional 
sodium clearance from about 0.2% to 3-4% (as could be expected 
of a distally acting diuretic); 
these effects of TA lasted about eight hours 
- plasma TA level and natriuretic effect correlated intraindi-
vidually and interindividually (p < 0.05); 
urinary TA level and natriuretic effect correlated also 
(p < 0.05 to ρ < 0.001), but only intraindividually; 
no correlation between drug level and uricosuric effect was 
found 
- marked interindividual differences existed in the linear re­
gression lines ("dose-response curves") of urinary sodium ex­
cretion against urinary TA excretion 
- an inverse relation was found between the starting plasma 
uric acid level in an individual and the maximal fractional 
clearance attained: the higher the plasma uric acid level, 
the lower the maximum effect 
- suggestive evidence was presented that the tubular transport 
of TA is saturated in the therapeutic dosage range 
After the withdrawal of TA from the market, we decided to study 
another diuretic: furosemide (F). 
Chapter VI describes the efforts made to develop a reliable 
method to determine F and its possible metabolites, especially 
in urine 
- in-vitro degradation of F (to CSA а.о.) occurred if F was ex­
posed to light in an acidic milieu: acidification if plasma 
is nevertheless necessary to separate F from its protein 
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binding and to extract it into the organic phase; acidification 
of urine is advisable to minimize the presence of endogenous 
fluorescing substances; apart from that, F fluoresces best at 
acidic pH, a characteristic used for detection 
- we succeeded in developing a specimen-handling procedure eli-
minating degradation of F; all specimens had to be protected 
carefully from light throughout the period from taking the 
specimen until injecting it into the column; if specimens were 
handled in this way, no trace of the controversial "metabolite" 
CSA was found 
- F was measured with an adapted HPLC method, using acetic acid 
instead of hydrochloric acid for deproteinization and extrac-
tion; F-gluc was hydrolysed using ß-glucuronidase, and total 
F was then measured in a second run. 
Chapter VIII describes some pilot experiments on F protein bin-
ding 
- under circumstances supposed to exist at the site of action 
of F, protein binding of F was far less (20-50%) than indi-
cated by data on protein binding of F in plasma (91-99%) 
- sulphamethizole did not displace F from its protein-binding 
sites in our experiment 
- the effects of F in the nephrotic syndrome were not enhanced 
by concomitant sulpha administration. 
The other questions posed about F on page 6 are dealt with in 
chapter VII, which describes our main study (published in two 
parts) : 
- pharmacokinetics of F in aged patients on long-term F treat-
ment were: V^ 0.16 ± 0.04 1/kg, total body clearance 73 ± 27 
ml/min, renal clearance 40 ± 18 ml/min and elimination half-
life 180 ± 87 minutes 
- the effects of 40 mg F i.v. in these patients were: 
diuresis 190-1900 ml, sodium excretion 2-225 mmol, and chlo-
ride excretion 7-250 mmol in the first 4 hours after injection 
- an increase in fractional sodium clearance was observed from 
0-0.2% to 0.5-20%, and an increase in fractional chloride 
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clearance from 0-0.4% to 2.7-30%; peak effects ranged from 
1 to 16 ml/min 
- the marked interindividual differences in effect observed on 
a standard F dose, prompted us to consider various aspects of 
diuretic resistance; this led to the construction of the 
table at the end of chapter III 
- figure 1 of chapter Vllb gives the relation between F ex-
cretion rate and fractional chloride (Fcl ); for all patients 
(except patient 8) and volunteers the rise in Fcl from 1 to 
5% took place in the excretion range from 10 to 75 ug/min; the 
relation between plasma F levels and effects was intraindi-
vidually just as good, but interindividually more variation 
in dose-response relation occurred, especially in the lower 
effect range (e.g. Fcl of 2% took place at plasma levels from 
0.3 to 3.2 mg/1 and Fcl of 10% occurred at plasma levels from 
0.9 to 3.3 mg/1 
- in comparison with data on groups of younger patients, the 
absorption of F in aged patients seemed slightly decreased; 
the volume of distribution was enlarged only in patients with 
low plasma protein levels. Total body clearance and renal 
clearance were markedly less, so the elimination half-life was 
prolonged; F effects in the aged did not differ from those in 
the young if the decreased renal delivery of F and the decrea-
sed glomerular filtration rate were taken into account 
- the major clinical problem stated in the introduction of this 
thesis concerns the question of individualized diuretic 
therapy in old age. In this context the simplest parameters 
(body weight, plasma urea or creatinine, urinary sodium or 
chloride concentration) proved to be unsuitable to predict 
F effects. Somewhat more sophisticated methods were useful: 
the measured ecc, but also the "ecc" as derived from a nomo-
gram using body weight, age, sex and plasma creatinine, corre-
lated well with effects. Many patient factors such as disease 
state, co-medication and especially the unpredictability of 
non-renal F clearance, limit the precision of any individua-
lized dosage. 
We nevertheless think that the risk of undertreatment or over-
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treatment can be reduced. Plasma creatinine per se is unreli-
able for this purpose in old people with their wide range of 
creatinine production. 
In treating old patients with F it should therefore become 
routine to measure ecc or deduce it from plasma creatinine, age, 
sex and body weight, using a nomogram. Starting and mainte-
nance doses can then be adapted accordingly: 
the lower the ecc, the larger the doses. 
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CHAPTER Χ 
SAMENVATTING 
Dit laatste, Nederlandstalige hoofdstuk is een beknopte weerga­
ve, in eenvoudige termen, van hoofdstuk IX waarin de wetenschap­
pelijke samenvatting en enkele slotbeschouwingen staan. 
Dit proefschrift beschrijft een klinisch-farmacologische studie 
over diuretica. 
Hoofdstuk I legt uit wat klinische farmacologie is (de weten­
schappelijk verantwoorde bestudering van geneesmiddelen en hun 
effect bij de (zieke) mens), waarom diuretica (vochtuitdrijvende 
middelen, 'plaspillen') zijn bestudeerd en welke vragen we hoop­
ten te kunnen beantwoorden. 
Hoofdstuk II beschrijft hoe de nieren het water- en zoutgehalte 
van het lichaam regelen, wat voor soorten diuretica er zijn en-
voor zover bekend - waar ze in de nier werken. Ook worden de 
twee bestudeerde geneesmiddelen voorgesteld (twéé, tiëniline 
zuur en furosemide (Lasix ), omdat het eerste plotseling uit de 
handel werd genomen, toen ons onderzoek al een eindweegs ge-
vorderd was. 
Hoofdstuk III zet uiteen welke gevolgen ouder geworden, lang-
durige behandeling en hartzwakte hebben op de lotgevallen 
(d.w.z. opname in, verspreiding in en verwijdering uit het 
lichaam) van geneesmiddelen. Het tevens veranderen van het ge-
neesmiddeleffect door al deze factoren wordt besproken en het 
verschijnsel van het soms vrijwel ontbreken van effect op diu-
reticumbehandeling (zgn diureticum resistentie). 
Hoofdstuk IV bevat beschrijvingen van een aantal gebruikte 
hulpmiddelen (apparaten en technieken): het apparaat waarmee 
de concentraties van de geneesmiddelen in bloed en urine wer-
den gemeten; de techniek om deze meetgegevens te verwerken en 
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te interpreteren (farmacokinetiek) en de achtergronden van onze 
methode om de gevonden geneesmiddelconcentraties in zinnig ver-
band te brengen met waargenomen effecten (dosis-effect relatie, 
farmacodynamie). Tevens wordt ingegaan op de binding van ge-
neesmiddelen aan bloedeiwitten. 
Hoofdstuk V bestaat uit het artikel over het onderzoek met 
tiëniline zuur. Een aantal stappen zijn hierin te onderkennen: 
het opzetten van een bepalingsmethode van het geneesmiddel, de 
bestudering van het verwerken ervan door het gezonde (jeugdige) 
lichaam en onderzoek naar het effect op het lichaam. Zowel 
omtrent de verwerking als over het effect kwamen enkele opmer-
kelijke zaken aan het licht. 
Hoofdstuk VI bevat een verslag van de problemen die werden ont-
moet bij het zoeken naar een methode om ons tweede studie-ob-
ject (Lasix) niet metoen buiten het lichaam te laten ontleden 
onder invloed van licht en zuur; de uiteindelijk gevolgde pro-
cedure en de bepalingsmethode worden beschreven. 
In hoofdstuk VIII zijn een aantal oriënterende onderzoekingen 
over de binding van Lasix aan eiwit samengevat. Deze eiwitbin-
ding werd speciaal bestudeerd in urine (niet in bloed), omdat 
dit geneesmiddel pas werkt nadat het in de nier vanuit het 
bloed naar de zgn ббг-игіпе is uitgescheiden. Er bestaat een 
groep nierziekten waarbij veel eiwit in de urine aanwezig is. 
De binding van Lasix aan eiwit bleek in urine veel minder te 
zijn dan in bloed, zodat voorlopig geconcludeerd werd, dat 
eiwitbinding van Lasix in de ббг-urine geen rol speelt bij 
diureticum-resistentie. 
Deze samenvatting besluit met de beschrijving van hoofdstuk 
VII, een verslag van het voornaamste onderzoek van dit proef­
schrift. We bestudeerden Lasix onder de omstandigheden waarin 
het meestal gebruikt wordt: langdurig, door oude mensen, die 
ook nog andere kwalen hebben. Deze patiënten hadden meer moeite 
oir het geneesmiddel te verwerken, terwijl het vochtuitdrijvend 
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effect bleek te zijn afgenomen. Beide fenomenen waren verklaar-
baar op grond van verminderde nierfunctie. 
In hoofdstuk IX wordt daarom bepleit om de nierfunctie van 
oude mensen zo nauwkeurig mogelijk te meten of te schatten en 
op grond hiervan de dosering van Lasix aan te passen (hoe 
slechter de nierfunctie, hoe meer Lasix); aldus kan waarschijn-
lijk de trefzekerheid van de behandeling met Lasix worden ver-
beterd. 
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DANKWOORD 
Bij de vo]tooiing van dit proefschrift wil ik graag allen be-
danken, die aan het totstandkomen ervan hebben bijgedragen. 
Dit geldt vooral voor de bejaarde patiënten, die met jeugdig 
elan aan het onderzoek hebben meegedaan. 
Het opzetten van meetmethodes voor de bestudeerde geneesmiddelen 
was mogelijk door de analytisch-chemische steun van wijlen Huub 
Ketelaars, de deskundigheid en accuratesse van Yuen Tan, en de 
schenking van analytisch zuivere geneesmiddelen (tienilinezuur 
1 4 door Smith, Kline & French Philadelphia USA; furosemide, C-
furosemide, N-benzyl CSA en CSA door Hoechst Frankfurt W-Duits-
land; ethacrynezuur door Merck Sharp & Dohme Rahway NJ USA). 
De heer J.H. Lintsen van de glasinstrumentmakerij prepareerde 
met grote zorg de HPLC kolommen. 
Bij de uitvoering van de klinische onderzoekingen heb ik de 
enthousiaste medewerking van verpleegsters en ziekenverzorgsters 
zeer gewaardeerd: van afdeling A52, A51, B50 en B40 van het St. 
Radboudziekenhuis, van de afdelingen 5, 6 en 7 van het verpleeg-
huis 'Irene' en van de interne afdelingen 1 en 21 van het 
Canisius-Wilhelminaziekenhuis. Door anderen gegeven steun werd 
gemeld in de dankwoorden van hoofdstuk V tot en met VIII. 
Het klinisch-chemisch laboratorium van de universiteitskliniek 
voor inwendige ziekten (hoofd Prof. Dr. A.P. Jansen) bepaalde 
de enkele bloed- en de vele urinemonsters. 
Harrie van Baars en Huub Cremers hadden, in het kader van hun 
medisch-wetenschappelijke stage, een belangrijk aandeel in de 
onderzoekingen gerapporteerd in hoofdstuk VII en VIII. 
Na afloop van een reeks experimenten werden de resultaten van 
de pharmacokinetische studies nader geanalyseerd met behulp van 
het FARMFIT computerprogramma door Coby Hurkmans. De meeste 
tekeningen werden vervaardigd door Cees Nicolasen. De manus-
cripten werden'enkele malen'getypt door Gemma Wessel - Hoog-
straaten en Leonne Tempelman. Anky Verweijen verzorgde de ver-
schillende versies van de inleidende en afsluitende hoofdstukken. 
Behalve alle bovengenoemden wil ik gaarne Prof. Dr. E.J. Ariëns 
bedanken voor zijn ondersteunende belangstelling voor dit onder-
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zoek. De verpleeghuisarts, collega К. Huinink was een grote 
steun tijdens een kritieke fase. De heer Th. van Winsen te 
Amsterdam corrigeerde snel en zorgvuldig het Engels (hoofdstuk 
I-VI, IX) en Amerikaans (hoofdstuk VII en VIII). 
Belangstelling voor de nier en voor urineonderzoek werd gewekt 
in 1957 (J. Kerremans sr) en gereactiveerd door J. Mattousch. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd 18 augustus 1949 in 
Roosendaal geboren. Vanaf 1961 bezocht hij het St. Norbertus-
lyceum in die stad en behaalde er in 1967 het eindexamen 
gymnasium B. Hij studeerde geneeskunde aan de Katholieke Uni-
versiteit te Nijmegen, waar het doctoraalexamen werd afgelegd 
in 1973 en het artsexamen in februari 1975. Vanaf 1 april 
1975 werd hij opgeleid tot internist in de Universiteits-
kliniek voor inwendige ziekten van het St. Radboudziekenhuis 
te Nijmegen (opleider Prof. Dr. C.L.H. Majoor); registratie 
als internist vond plaats in 1980. 
Vanaf 1979 is hij deels werkzaam op het Instituut voor Pharma-
cologie (Prof. Dr. E.J. Ariëns), deels op de afdeling algemene 
interne geneeskunde van de kliniek voor inwendige ziekten 
(Prof. Dr. A. van 't Laar) van het St. Radboudziekenhuis te 
Nijmegen. 
Momenteel bereidt hij een studieverblijf voor in de Verenigde 
Staten (Mayo Clinic,Minnesota), als Merck International Fellow 
in Clinical Pharmacology. 
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STELLINGEN 
1. De tabulaire secretie van tiënilinezuur raakt al bij normale 
therapeutische dosering verzadigd 
- dit proefschrift 
2. De grootte van het effect van urinezuur uitdrijvende middelen 
hangt af van de hoeveelheid tubulair gesecerneerd uraat 
- dit proefschrift 
- Lange F, Gregor R, Oberleithner H et al. Renal handling 
of urate in healthy man, in hyperuricaemia and renal 
insufficiency: circadian fluctuation, effect of water 
diuresis and of uricosuric agents 
Eur J Clin Invest 1980, 10, 285-292 
3. Ex vivo geneesmiddelontleding kan controversen omtrent 
geneesmiddelmetabolisme doen ontstaan 
- dit proefschrift 
- Upton RA, Buskin JN, Williams RL, Holford NHG, Riegelman S. 
Negligible excretion of unchanged Ketoprofen, naproxen 
and probenecid in urine. J Pharm Sci 1980, 69, 1254-1257. 
4. Niet alle renaal uitgescheiden geneesmiddelen hoeven bij 
gestoorde nierfunctie lager gedoseerd te worden. 
- dit proefschrift 
5. Reeds in zogenoemd phase II of III geneesmiddel-onderzoek 
zou de grootste patiënten doelgroep vertegenwoordigd 
moeten zijn. 
6. Furosemide-Glucuronide ontleedt in alkalisch milieu 
weer tot furosemide en glucuronzuur 
- Kerremans ALM, Gribnau Fï·'J, van Ginneken CAM. Metaboliet 
of artefact, koppelingsproduct of uitgangsverbinding? 
Ned Τ Geneesk 1983, 127, 132. 
7. Bij onverklaarde, chronische monarthritis dienen synovium-
biopten ook te worden gekweekt op Löwenstein voedingsbodeirs 
- Kerremans ALM, Boerbooms A, Slooff TJJ et al. Monarthritis 
met niet verkazende ( epithelioide) granulomen in het 
synovium. Ned Τ Geneesk 1980, 124, 1464-1467. 
8. Bij een geneesmiddelreactie tijdens multipele therapie zal 
men deze veelal wijten aan "het meest verdachte" geneesmiddel 
Ook zeer zeldzame geneesmiddelreacties komen anderzijds 
écht voor. Gebruik van bijwerking-algoritmen kan dan de 
"klinische indruk" ondersteunen 
- Kerremans ALM, Majoor CLH, Gribnau FWJ. Hypersensitivity 
to ethambutol. Tubercle 1981, 62, 215-217. 
9. Tiënilinezuur versterkt de werking van acenocoumarol en van 
andere anticoagulantia, waarschijnlijk niet door verdringing 
uit plasma-eiwit binding, maar door remming van metabolisme 
- eigen waarneming (zie figuur) 
- O'Reilly RA. Tiorynafen/racemic-warfar in interaction. 
Clin Pharmacol Ther 1982, 32, 356-361. 
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10. Ook bij de behandeling van intoxicaties dient de therapie 
minder riskant te zijn dan de oorspronkelijke noxe 
- Wright N. Common errors in the management of poisoning. 
J Roy Coll Phys Lond 1980, 14, 114-116. 
11. Al vele eeuwen eindigt de ontmoeting met de arts in een 
aderlating: "therapeutisch", "diagnostisch", dan wel finan­
cieel 
- Seighworth GR. Bloodletting over the centuries. 
New York State J Med 1980, 80, 2022-2028. 
12. Bij bejaarden kan zowel vocht opnemen als vocht kwijtraken 
problematisch worden 
- Miller PD, Krebs RA, Neal ВJ, Mclntyre DO. Hypodipsia in 
geriatrie patients. Am J Med 1982, 73, 354-356. 
- Williams ME, Pannili FC. Urinary incontinence in the elder­
ly. Ann Intern Med 1982, 97, 895-907. 
13. De door Descartes voorgestelde totale scheiding van de mens 
in 'lichaam' en 'geest' heeft grote ontwikkelingen in de 
geneeskunde mede mogelijk gemaakt (doordat de bestudering 
van 'het lichaam' aan de controle van de Kerk werd onttrokken) . 
Momenteel is deze scheiding veeleer een rem op verdere ont­
wikkeling 
- Bertrand Russell. History of Western Philosophy; 1969, 
London. Unwin University books, 542-551. 
- Cassel EJ. The nature of suffering and the goals of medi­
cine. N Engl J Med 1982, 306, 639-645. 
14. De farmacotherapie van Nederlandse patiënten, het onderwijs 
over (gebruik van) geneesmiddelen aan toekomstige artsen, 
en het onderzoek omtrent geneesmiddelen bij de mens, zijn 
gebaat met de beschikbaarheid van een ruim aantal medici in 
ons land, die zich speciaal in klinische farmacologie be-
kwaamden. Het is wenselijk dat deze bekwaming c.q. opleiding 
gestructureerd wordt en uitmondt in een erkenning als (deel-) 
specialist, eventueel in de vorm van een 'aantekening'. 
15. Goede farmacotherapie is niet gediend met politieke beslis­
singen over geneesmiddelen 
- Meulenhoff JS. Vasolastine meer dan miserabel. Ned Τ Ge-
neesk 1980, 124, 2228-2229. 
- Lasagna L. The Halcion story: trial by media. Lancet 1980, 
1 , 815-816. 
Dukes MNG. The "Van der Kroef syndrome" in Side Effects 
of Drugs Annual IV, 1980, Amsterdam, Excerpta Medica. 
- Editorial.Rejecting Scientific advice (on depo-provera) 
Br Med J 1982, 284, 1426. 
16. Het plasma kalium gehalte zal me een zorg zijn 
- Harrington JT, Iner JM, Kassirer JP. Our national obsession 
with potassium; Editorial Am J Med 1982, 73, 155-159. 
17. Men is nooit te oud om van te leren. 
Nijmegen, januari 1983 A.L.M. Kerremans 

